2Q26 EPS beat still 24% above consensus after normalization

Reported adjusted EPS of $2.58 beat $1.85 pre-print consensus by 39%. Approximately $500M of HCB adjusted operating income came from the 2025 exchange risk-adjustment update and favorable prior-year development. Applying the 24.9% full-year tax assumption and approximately 1.287B diluted shares produces an estimated $0.29 per-share benefit and a normalized EPS proxy of about $2.29. That is still roughly $0.44, or 24%, above consensus.

The result also had support outside Aetna. Health Services adjusted operating income was $1.7B versus $1.5B consensus. Pharmacy & Consumer Wellness (PCW) produced $1.5B of adjusted operating income versus $1.4B consensus. PCW comparable sales increased 2.6% against a 0.9% expected decline, led by pharmacy. Management said Health Services included an unspecified pull-forward from the second half and that underlying performance was roughly in line with expectations after excluding it. Broader Caremark and specialty-generic strength offset 340B pressure, but the full-year Health Services floor remained at least $7.25B. The segment beats extended beyond HCB, but the Health Services pull-forward and unchanged full-year guidance argue against carrying its full quarterly variance into the second half.

2026 adjusted EPS baseline increased about 3.5%

CVS raised its 2026 adjusted EPS range to $7.90-$8.10 from $7.30-$7.50, moving the midpoint to $8.00 from $7.40. The company then removed $0.54 of known favorable first-half items to establish a $7.46 baseline. The $7.45 pre-print consensus is assumed to have fully incorporated the first-quarter benefit, which Graver Research estimates at approximately $0.25 per share from the disclosed $420M HCB guide increase. Removing that amount creates a derived clean pre-print hurdle of about $7.20. On that like-for-like basis, the current baseline is approximately $0.26, or 3.5%, above the derived $7.20 hurdle, compared with the reported $0.60, or 8.1%, increase in the guidance midpoint.

_{Sources: CVS Health; StreetAccount; Koyfin; Graver Research calculations.}

The higher base has identifiable operating and cash support. HCB’s full-year adjusted operating-income midpoint increased $1.0B to $5.2B, and the PCW floor rose $220M to at least $6.4B. Together they exceed the $1.1B increase in CVS’s enterprise midpoint, implying an approximate $200M offset elsewhere that cannot be assigned cleanly. Health Services adjusted operating-income guidance did not change. After subtracting the known $420M and $500M HCB items, a simple Graver Research proxy puts the HCB guide at $4.28B, about $530M above the 2025 Investor Day midpoint. Operating cash-flow guidance also increased to at least $11.5B from at least $9.5B. The normalized EPS increase has segment and cash-flow support, but the guidance changes remain concentrated in HCB.

HCB remained above consensus after normalization

HCB provides the quarter’s strongest evidence. Reported adjusted operating income of $2.4B was far above $1.5B consensus. Removing all $500M of disclosed favorable items leaves a proxy of approximately $1.9B, still $466M, or 32%, ahead of consensus. The same test holds for the medical benefit ratio. Reported MBR of 87.4% was 240 bps favorable to 89.8% consensus; adding back the disclosed 140 bps benefit produces an 88.8% normalized proxy, still 100 bps favorable.

_{Sources: CVS Health; StreetAccount; Graver Research calculations.}

Neither the reported nor normalized second-quarter MBR should be treated as a second-half run rate. First-half HCB adjusted operating income rose 66% to $5.5B, but the comparison includes far fewer premium-deficiency reserve (PDR) charges. The second quarter of 2025 contained a $471M group Medicare Advantage PDR, and first-half 2025 health-care-cost PDR components totaled $902M versus a new $15M Medicaid PDR in first-half 2026. Management also expects HCB MBR to rise slightly more than 950 bps from the adjusted first-quarter level to the fourth quarter. About 75% of the group MA book had been renewed or priced, and 2027 bids assume continued elevated trend. Pricing, Medicare mix and medical-cost execution support the recovery case, but the PDR comparison and expected second-half MBR increase leave normalized earnings power unproven.

Caremark is the main constraint on 2027 upside

Caremark is the main constraint on upside to the preliminary 2027 EPS floor. CVS secured more than $6B of new sales in the prior selling season, above its historical average, and described 2027 retention as slightly below its own history but closer to industry norms. At the same time, management identified two sources of membership loss: contracts CVS chose not to retain as it shifted toward lowest-net-cost models, and health-plan customer product actions or market exits. CVS did not quantify net membership, the related adjusted operating-income effect, the timing of new business or the 340B headwind. The unchanged Health Services floor and unsized second-quarter pull-forward further limit the earnings read-through from the quarterly beat. The lack of upside to the $8.44 floor is more closely tied to unresolved Caremark retention and economics than to Aetna.

Specialty pharmacy, the 2027 generic pipeline, biosimilars and Cordavis, PCW, and further delivery execution provide offsets. The $8.44 floor also assumes only dilution-offsetting repurchases. While the FTC agreement reduces one source of legal uncertainty, it still does not create needed certainty about 2027. Announced before the print, the FTC consent package had been accepted for public comment but is still not a final order. Proposed terms include a standard offering tied more closely to contracted net cost, point-of-sale rebates, limits on list-price-linked compensation, transparency and community-pharmacy protections; custom terms remain possible after disclosure and written acknowledgment. Implementation is staged: some provisions take effect by an implementation date no later than January 1, 2027, while several substantive standard-offering provisions begin January 1, 2028. CVS says much of the work was underway, but it has not quantified implementation costs or the P&L effect. The disclosed offsets support the achievability of $8.44, but CVS has not provided enough Caremark or implementation detail to treat the floor as conservative.

The 11% selloff far exceeded outer-year estimate revisions

CVS rose 30.2% from May 5 through the August 4 pre-print close, compared with 12.1% for XLV. It then fell 5.1% on August 5 and 11.0% through August 27, while XLV gained 5.8%. Over the post-print period, FY26 adjusted EPS consensus increased 6.7%, but FY27 and FY28 rose only 0.9% and 0.6%. CVS materially outperformed XLV before the print and then fell far more than FY27 and FY28 consensus changed. Clearly investors were hoping for more clarity on the second quarter call.

_{Source: Koyfin.}

_{Source: Koyfin.}

CVS is not necessarily cheap: its 11.4x NTM P/E is above its 10.5x ten-year median, but below its 12.2x plus-one-standard-deviation level. First-half operating cash flow of $10.6B less $1.5B of capital spending produces a simple $9.1B free-cash-flow proxy, and CVS repaid $3.3B of debt. CVS’s 3.5x net-debt leverage is down from 4.0x at year-end 2025, although first-half cash benefited from working-capital improvements and should not be annualized. Cash generation and lower leverage reduce balance-sheet risk, but multiple expansion requires operating evidence that 2027 adjusted EPS can exceed $8.44.

The remaining tests are HCB durability and Caremark economics

2Q26 established a higher and more credible $7.46 earnings base. A stronger thesis requires HCB adjusted operating income and MBR to remain better than consensus after favorable items roll off, without new material PDRs. Caremark wins need to offset membership losses at acceptable economics, 340B pressure must be contained or quantified, and formal 2027 segment guidance needs to support a result above the preliminary $8.44 floor. Cash conversion and deleveraging also need to continue. Another strong HCB quarter alone will not clear up the valuation story here; investors need more clarity on Caremark too. Moderate Caremark attrition will not invalidate the thesis if margins and consolidated earnings hold. HCB reversion, new reserve charges, weaker retention or dependence on incremental buybacks would weaken it. Q2 strengthened the Aetna recovery case; 2027 upside still depends on quantified Caremark retention and adjusted operating-income expectations.

Subscribe now

Profit conversion carried the beat

Revenue of $84.8B was about $445M above consensus. Adjusted gross margin of 4.16% beat by 30 bps, total segment operating income rose 17.0% to $1.2B and adjusted operating margin expanded 15 bps to 1.46%. The operating-income surprise slightly exceeded the adjusted EPS beat, while adjusted net income grew 11.2% and adjusted EPS grew 12.0%. The profit-led surprise is more supportive of the operating case than the modest revenue beat alone. But the 61 bps year-over-year gross-margin increase was largely due to the February OneOncology acquisition, so the increase partly reflected mix rather than underlying margin expansion.

_{Sources: Cencora F3Q26 earnings release; StreetAccount.}

U.S. Healthcare Solutions provided the clearest evidence of underlying profit strength. Revenue of $74.9B missed consensus by 0.4%, but segment operating income rose 15.9% to $966M, 2.8% above consensus, and margin increased 12 bps to 1.29%. GLP-1 sales added $2.3B of year-over-year revenue, while manufacturer list-price reductions created a $2.4B headwind to revenue growth. The prior-year loss of an oncology customer and lower sales to a large mail-order customer also weighed on revenue. Against that backdrop, specialty growth was strong across the MSOs, health systems and physician practices, while the core U.S. business delivered double-digit organic operating-income growth excluding OneOncology and the lost customer. The revenue miss matters less than the segment’s profit resilience through price and customer noise.

OneOncology outperformed, but the 12-month EPS outlook remains neutral

OneOncology and Retina Consultants of America both performed ahead of management’s expectations, and OneOncology operating income was modestly better than initially expected. That supports the strategic rationale for adding physician-practice platforms around Cencora’s specialty distribution and GPO capabilities. It does not yet prove per-share accretion. On a 12-month basis, management still expects OneOncology to be neutral to adjusted EPS net of financing. F3Q26 net interest expense increased $59M year-over-year, primarily because of acquisition financing. Integration is progressing, but management said cross-platform clinical-trial capability sharing remains early, while new analytics and service offerings are future-stage opportunities.

International broadened the beat, although one timing benefit will not repeat in F4Q26. Segment operating income rose 20.8%, or 23.1% in constant currency, to $166M and beat consensus by 1.8%. World Courier and European 3PL each delivered double-digit profit growth, but European distribution again benefited from the timing of manufacturer price adjustments in a developing market, which management does not expect in F4Q26. Other operating income rose 24.8% to $109M and beat by 10.6%, but management said the majority of the growth came from held-for-sale accounting, which reduced depreciation expense; underlying MWI growth was about 10%. Every segment beat, but the U.S. result carries the strongest evidence of repeatability, International needs a timing adjustment, and Other was the lowest-quality contributor.

_{Sources: Cencora F3Q26 earnings release and call; Graver Research analysis.}

Segment profit supported the adjusted EPS beat

GAAP EPS of $3.94 was $0.54 below adjusted EPS, but the net gap contained large offsetting items. The reconciliation added back $0.60 for deal and integration expenses, $0.32 for intangibles amortization and $0.18 for restructuring; LIFO and litigation/opioid credits reduced the bridge by $0.31 and $0.35, respectively. The adjusted result was still supported by the segment-profit beat, rather than created by exclusions. Capital allocation also helped: Cencora repurchased $1.0B of stock at an average $268 per share, and diluted shares fell 0.7% to 193.9M. Buybacks are part of the company’s earnings algorithm, but their contribution does not prove organic growth or OneOncology accretion.

_{Source: Cencora fiscal Q3 2026 earnings release, GAAP-to-adjusted reconciliation.}

The raise de-risked FY26 without lifting the implied F4Q26 EPS path

On August 4, FY26 adjusted EPS consensus was $17.78 and F3Q26 consensus was $4.35. With $8.83 of adjusted EPS already earned in the first half, the pre-print path implied $4.60 for F4Q26. The new $17.85 guidance midpoint, less nine-month adjusted EPS of $13.31, implies $4.54 for F4Q26. In other words, the $0.05 midpoint raise captured less than half of the $0.13 F3Q26 beat, leaving the midpoint-implied F4Q26 EPS path about $0.06 below the pre-print path. The guide raised the FY26 floor, but it did not establish a higher exit rate. A lower share-count assumption also supported EPS, while net-interest guidance increased by $5M to approximately $490M following the repurchases.

F4Q26 still requires a strong operating and cash finish. Cencora raised consolidated adjusted operating-income growth guidance to 13%–14% from 12%–14%, narrowed U.S. growth to 14.5%–15.5%, and lifted International and Other to approximately 9% and 10%.Using the midpoint or point guidance and the recast FY25 bases, Graver Research calculates that F4Q26 total segment operating income would need to grow about 20.1% year-over-year. Management expects F4Q26 to deliver the strongest U.S. organic growth of FY26, excluding OneOncology, at the guidance midpoint, as the lost oncology customer is fully lapped and expenses become easier. Adjusted free cash flow adds another back-end test: $1.1B through nine months against an unchanged approximately $3.0B target leaves about $1.9B, or 62% of the annual goal, for F4Q26. Cencora’s cash flow is seasonally weighted to its fiscal fourth quarter, but the F4Q26 conversion still has to occur.

_{Sources: Cencora fiscal Q2 and Q3 2026 earnings materials; Koyfin consensus; FY2025 segment recast; Graver Research analysis.}

FY26 estimates rose; FY27 did not

COR rose 3.6% on August 5 and was 3.8% above the August 4 close through August 21, versus a 0.8% decline for the S&P 500 and a 7.7% gain for XLV. FY26 EPS consensus increased $0.09 to $17.87 over that period, while FY27 consensus slipped $0.03 to $19.79. The stock is currently trading near 17.0x NTM EPS, modestly above its 10-year plus-one-standard-deviation level and nearly 2 turns above the 13.8x median. That premium leaves less room for an incomplete FY27 bridge. Assuming a midyear close, management’s MWI-Covetrus modeling implies a $150M FY27 operating-income headwind in Other and an approximately $0.35 EPS headwind; management advised investors not to include EyeSouth in models because its timing remains uncertain. The November guide has to show whether core growth, OneOncology and capital deployment can offset the modeled MWI headwind.

The next test is the FY27 bridge

F3Q26 showed that Cencora’s specialty platform and core distribution economics can deliver through price and customer noise. It also reduced OneOncology execution risk and made FY26 more achievable. What remains unresolved is whether OneOncology becomes accretive net of financing, whether International and Other can grow after the timing and accounting benefits normalize, and whether F4Q26 converts earnings into the cash embedded in guidance. The F4Q26 result and November FY27 outlook are therefore the next tests. U.S. organic acceleration, logistics growth without another price-timing benefit, full-year cash conversion and an FY27 guide that absorbs the MWI headwind without relying on outsized repurchases would strengthen the case that F3Q26 momentum can carry into FY27. Another timing-supported beat, weak cash conversion or a lower FY27 earnings base would leave the normalized FY27 case unresolved. For now, the FY26 case improved more than the normalized FY27 case.

Subscribe now

Distribution economics carried the beat

The North American Pharmaceutical segment was the strongest driver of the beat. Revenue of $86.773B was 0.8% below consensus, as January WAC reductions and branded-to-generic conversions weighed on reported top-line growth. Adjusted operating profit, however, rose 19% to $894M, 10.8% above consensus, and margin expanded by 12 bps to 1.03%. Management clarified two items: (1) lower WAC reduced reported revenue but had little effect on profit because McKesson recognizes branded-drug revenue at the drug’s selling price, while more than 95% of its branded-drug contracts compensate it on a fee-for-service basis; (2) branded-to-generic conversions benefited gross profit, despite reducing reported revenue. Specialty distribution to health systems and strategic accounts, along with new-product-launch timing, also drove the year-over-year profit increase. GLP-1 distribution revenue reached $15B, up 24% year-over-year; they did not disclose GLP-1 profit growth. The best characterization of the segment’s quarter is that lower WAC and branded-to-generic conversions obscured the top-line result, while specialty volume, favorable launch timing and the gross-profit benefit from those conversions drove the operating profit beat.

The Oncology & Multispecialty segment also supported the beat. Revenue grew 33% to $14.222B and adjusted profit rose 41% to $405M, 6.6% above consensus; excluding Core Ventures, management estimated growth of roughly 24% and 15%, respectively. The Prescription Technology Solutions segment was healthy but less incremental: revenue and adjusted profit rose 9% and 13% to $1.566B and $303M, with profit exactly in line with consensus. In dollar terms, North American Pharmaceutical and Oncology & Multispecialty contributed $263M of the $229M year-over-year increase in consolidated adjusted operating income, before Medical-Surgical and other offsets.

^{Sources: McKesson; StreetAccount; Graver Research calculations.}

The raise mostly banked the F1Q27 beat

The full-year EPS bridge is where the constructive read needs to be tempered. Prior to the report, FY27 and F1Q27 adjusted EPS consensus sat at $44.26 and $9.56, respectively. That implied F2Q27–F4Q27 pre-print adjusted EPS consensus at $34.70, while the updated guidance midpoint implies $34.67 of adjusted EPS for F2Q27–F4Q27. That leaves a straightforward implication: the $0.40 range increase largely banked the $0.37 F1Q27 beat. Management may still outperform, but the raise itself did not establish a higher F2Q27–F4Q27 earnings path.

Management’s full-year segment outlook embeds the same pattern. For NAP and Oncology the outlook assumes a much slower pace of growth after their unusually strong F1Q27 results, while the RxTS outlook assumes steady growth, and Medical-Surgical assumes a recovery. If NAP finishes at the high end of its profit-growth range, its combined F2Q27–F4Q27 profit would need to grow about 6.8% year-over-year, versus 19.4% in F1Q27. Using the midpoint elsewhere, Oncology’s remaining-year growth is approximately 9.1% after 41.1% in F1Q27, although acquisition timing makes that comparison less indicative of underlying momentum. RxTS remains near its F1Q27 pace, while Medical-Surgical must swing from a 20.1% decline in F1Q27 to roughly 8.9% growth over the remaining three quarters. Those calculations fit with management’s explanation that some generic and launch favorability arrived early, while higher investment in growth and AI is concentrated in the second half.

^{Sources: McKesson Q4 FY26 and Q1 FY27 earnings releases and Q1 FY27 earnings presentation; Graver Research calculations.}

McKesson raised consolidated adjusted operating-profit growth guidance to 9%–13% from 8%–12% and now expects NAP to finish at the high end of its 5.5%–9.5% range. The gap between NAP’s 19.4% F1Q27 growth and its 6.8% F2Q27–F4Q27 hurdle leaves room for a meaningful slowdown if specialty demand moderates or F1Q27’s timing favorability creates a larger second-half payback. Higher second-half investment is already embedded in the full-year outlook, while the 50 bps increase in the midpoint of the tax-rate range limits how much of the improved operating outlook reaches EPS. Guidance may still prove conservative, but the raise itself did not prove that; F2Q27–F4Q27 delivery must do that.

Medical-Surgical and cash remain the exceptions

The Medical-Surgical segment is the clearest reason not to call the quarter uniformly high quality. Revenue rose 4% to $2.819B and modestly exceeded consensus, but adjusted profit fell 20% to $195M, 21.1% below the $247.1M pre-print consensus, and drove a 211 bps margin decline to 6.92%. Management attributed the weakness to product mix and one-time administrative expenses, partly offset by extended-care growth. That explanation may be right, but the unchanged flat-to-4% full-year profit outlook now requires roughly 8.9% growth over F2Q27–F4Q27 at the midpoint. The segment remains in consolidated results while the Wellverse separation advances, so its margin recovery still matters to near-term earnings quality.

The GAAP bridge was also unusually large. GAAP EPS of $5.15 was $4.78 below adjusted EPS, largely due to transaction and separation accounting. The $3.85 per-share transaction adjustment included a $293M remeasurement of Apollo’s redeemable minority interest; restructuring/impairment and amortization added another $0.82 and $0.41. But operations still led the adjusted result. McKesson attributed $1.41 of the $1.67 year-over-year increase to operating performance, versus $0.50 to capital allocation and a $0.24 drag from other items. Buybacks supplied about 30% of growth, material but secondary.

Cash conversion improved, but still remains a key nit-to-pick. F1Q27 free cash flow was negative $372M, versus negative $1.107B a year earlier, as working-capital execution improved. Management correctly noted that McKesson’s fiscal first quarter is seasonally negative and said much of the change was structural. But FY27 free-cash-flow guidance stayed at $4.5B-$4.9B. The $4.7B midpoint is about 13% below FY26’s $5.410B result even as adjusted EPS is expected to grow 15%-17% from the company’s normalized base. One better seasonal quarter lowers the concern at the margin. A raised full-year cash outlook or sustained working-capital improvement would do more to validate the earnings path.

The stock moved more than the estimates

MCK had already risen 5.6% to $877.23 on August 5 before its after-market-close report, likely helped by a positive read-through from Cencora’s before-market-open earnings beat and guidance raise; COR gained 3.6% that day. In the first post-print session, MCK shares opened another 4.0% higher but closed at $871.38, down 0.7% from the prior close. By August 21, MCK was at $858.90: down 2.1% from the August 5 baseline but still 3.4% above August 4. Over the same August 4-August 21 window, FY27 EPS consensus rose $0.37 to $44.63 and FY28 moved only $0.18 to $50.56. At 18.4x NTM EPS, versus a 10-year median of 12.5x and a +1 standard-deviation level of 17.0x, the stock already requires more than a good F1Q27 report.

^{Sources: Koyfin price and consensus histories; McKesson and Cencora earnings releases; StreetAccount; Graver Research analysis.}

The next proof is outer-quarter delivery

The F1Q27 report showed solid growth in distribution profit while WAC reductions pressured recognized revenue, with Oncology providing a second operating engine, RxTS remaining solid, and the portfolio overcoming weakness in Medical-Surgical. However, it was helped by early generic and launch benefits, and left the implied F2Q27–F4Q27 EPS path essentially unchanged from pre-print consensus. The most useful next test is measurable: NAP needs to meet or beat the roughly 6.8% implied F2Q27–F4Q27 profit path without another pull-forward, Medical-Surgical needs to show the recovery embedded in guidance, and FY27 cash flow and FY28 estimates need to move with earnings. A raised cash outlook, sustained outer-year revisions and cleaner Medical-Surgical revenue-to-profit conversion would strengthen the interpretation. More timing benefits, another segment miss or a buyback-led beat would leave it roughly where it stands. For now, the operating case improved more than the forward earnings case.

Subscribe now

That distinction matters after the stock’s recent move. IQV rose 21.9% from the July 27 pre-print close through August 21, while consensus FY27 adjusted EPS and EBITDA increased just 1.9% and 1.2%, respectively. The market is no longer waiting for proof that demand has stabilized; it has started to capitalize a better 2027. That is not the same as saying the shares are expensive in absolute terms, but it does mean the burden of proof has changed. Further upside should depend less on another healthy bookings quarter and more on evidence that revenue conversion will carry operating leverage.

The recovery is becoming harder to dismiss

The 2Q26 print beat consensus in the places that mattered most. Revenue of $4.368B was $68M, or 1.6%, above consensus. Adjusted EBITDA of $994M beat by $29.5M, or 3.1%, and adjusted EPS of $3.15 beat by $0.12, or 4.0%. R&DS revenue was $65M/2.6% above consensus and accounted for approximately 96% of the companywide revenue beat; Commercial was only $3M/0.2% ahead. Book-to-bill reached 1.22x versus a 1.11x expectation. The one clear shortfall was backlog, which ended at $34.2B compared with the $34.5B expectation.

Bookings were more important for proving out the recovery than the quarterly beat. Net awards increased 19.3% year-over-year and 27% sequentially to the highest level since 2022. Management said the result was broadly based, with no oversized contract and normal cancellations, pass-through content and therapeutic mix. FSP awards remained at their normal low- to mid-double-digit share of total bookings, while full-service bookings were particularly strong. Last-twelve-month bookings rose for a fourth consecutive quarter to $11.25B, up 12.9%. RFP flow increased at a double-digit rate both sequentially and year-over-year, and decision timelines shortened.

The resulting backlog is one nit to pick against the strong bookings data. The $34.2B balance was flat sequentially and only $0.2B above recast year-end backlog, even as next-twelve-month backlog revenue rose 7.5% to $9.23B. IQV could adjust backlog by roughly 5% for inactive trials when it completes the review in the third quarter. Importantly, management said any adjustment would not affect historical results, guidance or next-twelve-month revenue from backlog. That frames it as backlog hygiene rather than an identified near-term earnings risk, but the tail remains unclean until the work is complete. Flat backlog does not negate stronger bookings, but it does prevent the quarter from proving a fully normalized book at the moment.

^{Sources: IQVIA; StreetAccount/FactSet; Graver Research analysis.}

The guidance raise adds revenue without lifting implied 2H26 profit

The full-year outlook improved, but mainly at the top line. IQV raised the 2026 revenue midpoint by $125M to $17.375B, adjusted EBITDA by $25M to $4.025B, and adjusted EPS by $0.10 to $12.90. The new midpoints are $85M, $25M and $0.09 above pre-print consensus. Management’s bridge added roughly 100 bps of organic growth and 50 bps from acquisitions, partly offset by an FX tailwind that was 80 bps smaller than in prior guidance. 3Q26 revenue guidance was about $36M above consensus at the midpoint, while adjusted EBITDA and EPS were essentially in line. That guidance mostly de-risks growth. It does not imply incremental 2H26 earnings versus the prior framework.

The residual bridge makes that distinction clearer. Subtracting 1Q26 actuals and the prior 2Q26 midpoint from the former full-year midpoint yields $8.789B of implied 2H26 revenue, $2.103B of adjusted EBITDA and $6.87 of adjusted EPS. Subtracting 1Q26 and 2Q26 actuals from the updated midpoint produces $8.856B, $2.099B and $6.85. On that basis, the new framework contains $67M more 2H26 revenue but $4M less adjusted EBITDA and $0.02 less adjusted EPS.

^{Sources: IQVIA; Graver Research calculations.}

The operating improvement was real, but earnings quality was mixed

Adjusted EBITDA margin expanded by about 10 bps to 22.76%. Management attributed roughly 90 bps of underlying margin expansion to operating and productivity programs, offset by approximately 80 bps of pass-through pressure; FX was negligible. Commercial and R&DS segment profit margins each improved by more than 40 bps. R&DS revenue grew 8.8% as reported but 6.7% excluding reimbursed expenses; acquisitions contributed about 2.5 points of company growth, and management expects the Charles River assets to add $75M-$80M to 2026 revenue at lower margins. Productivity is showing through, but mix still absorbed most of it. That’s good progress, but not yet a clean operating-leverage inflection.

Earnings quality was mixed rather than poor. Adjusted net income increased 8.4%, while adjusted EPS rose 12.1% as diluted shares declined 3.4%. GAAP operating income was flat, and selected stock-compensation and restructuring add-backs increased by a combined $60M. Restructuring is expected to continue through 2026 and into 2027, so it is not an isolated charge. The counterweight is cash: free cash flow increased 23.3% to $360M, and IQV repurchased $398M of shares. The operating story has cash support, but EPS growth was not entirely operational.

Outside evidence also supports demand recovery

The external evidence points in the same direction. MEDP’s net awards increased 28.2% to $795.7M, producing a 1.13x book-to-bill ratio, as RFP activity and opportunity quality improved. More than half of the sequential bookings gain, however, came from fewer cancellations. TMO reported strong authorizations at PPD and said awards typically take about six months to reach revenue. BioWorld provides a useful funding cross-check: 1H26 biopharma financing more than doubled to $60.14B, and the $67.65B raised through July was the fourth-highest total for the period. These signals support IQV’s demand story.

Peer anecdotes also show why bookings should not be confused with near-term profit. ICLR’s headline book-to-bill was 1.51x, but 1.20x on direct fees; revenue increased 1.2% while adjusted EBITDA fell 21.7%. FTRE posted quarterly and trailing ratios of 1.06x and 1.12x, yet revenue declined 4.5%.

IQV’s AI disclosures are also promising but incomplete: 294 agents span 90 use cases, with IQVIA solutions deployed in the workflows of 19 of the top 20 pharmaceutical companies and AI co-development work with four top-10 customers. IQV has not quantified the revenue, savings or returns. FTRE said AI is in most RFPs but is not the primary decision factor; ICLR expects discovery-led capacity effects to take years. AI may support IQV’s competitive position, but it is not yet an earnings claim.

The stock now requires profitable conversion

Expectations have moved much faster than estimates. IQV advanced from $213.22 on July 27 to $259.82 on August 21, a 21.9% gain. Consensus FY26 and FY27 adjusted EPS increased just 1.25% and 1.91%, while adjusted EBITDA rose 0.90% and 1.20%. The move should be seen more as a valuation rerating than as an earnings revision. Valuation does not support an obvious absolute-bear case: IQV now trades at 13.7x NTM EV/EBITDA and 19.0x NTM P/E, modestly below its 10-year medians. The issue is that more of the recovery is now reflected before the related profit has arrived.

^{Sources: Koyfin; Graver Research analysis.}

The 2Q26 print established that IQV’s growth, bookings and external demand indicators are finally moving together. It did not settle the economics of 2027 conversion, resolve the backlog review, prove sustained margin leverage, or attach financial value to AI. The next evidence will be the 3Q26 print and backlog review, the December 2 Investor Day and, ultimately, the initial 2027 framework. Sustained book-to-bill above 1.0x, continued growth in next-twelve-month revenue from backlog and visible operating leverage would strengthen the interpretation. A bookings reversal, weaker conversion, a larger backlog adjustment or continued mix dilution would weaken it. The debate has moved from whether demand is stabilizing to whether IQV can turn it into profitable 2027 growth.

Subscribe now

The quarter also cleared the July 29 hurdle on more than EPS. EPS beat by $0.18, or 2.4%; revenue of $71.67B was 2.2% above consensus; Evernorth and Cigna Healthcare adjusted operating income beat; and the 84.5% MCR was 50 basis points favorable to consensus. Despite the strong print, management raised the 2026 EPS floor by only $0.10, to $30.45—effectively matching the $30.46 preprint consensus. Said another way, the print protected the 2026 floor more than it lifted the earnings path, which is ultimately more important for valuation.

^{Sources: CI 2Q26 earnings release and financial supplement; StreetAccount; Graver Research calculations.}

How CI absorbed the PBS reset

PBS adjusted income fell by $224M year-over-year, while Specialty and Care Services added $191M, offsetting approximately 85% of the decline and leaving Evernorth down only $33M. Cigna Healthcare contributed another $182M. Corporate and Other was a $32M drag, partially offset by $7M of lower tax expense. These changes reconcile to a $124M increase in consolidated adjusted income.

^{Sources: CI 2Q26 financial supplement; Graver Research calculations.}

Share repurchases provided modest support to headline EPS growth. Diluted shares declined 1.6% year over year, adding roughly 1.6 percentage points to the 8% increase in adjusted EPS; adjusted income rose 6%. The $30.45 full-year EPS floor represents only about 2% growth from 2025 and already assumes additional share repurchases. The quarter therefore increased confidence that Cigna can deliver modest EPS growth through the PBS reset, but it did not establish a return to the company’s 10%–14% long-term algorithm.

The offsets are credible, but not a new run rate

Specialty growth looks like the most credible offset, but +22% year-over-year is not the right run rate. Management said some of the benefit from faster generic and biosimilar adoption arrived earlier than expected, and some economics shifted from PBS into Specialty. Those factors make the $191M increase real, but also limit its repeatability. Cigna’s long-term framework calls for 8%-12% Specialty adjusted-income growth, a more appropriate baseline than annualizing the second quarter. The question for 2027 is not whether Specialty can grow, but whether normalized high-single- to low-double-digit growth can still cover continued PBS pressure once earlier timing and the shift of economics out of PBS stop helping the comparison.

Cigna Healthcare also provided real support, though the earnings quality was less clean than the 17% growth rate suggests. Adjusted operating income of $1.276B beat consensus by roughly $59M, and the 84.5% MCR was 50 bps favorable to the Street despite deteriorating by 130 bps year-over-year. Net investment income was $175M, $59M above consensus and $48M above 2Q25. Separately, 50 bps of MCR on $9.66B of premiums equates to approximately $48M of pretax income. Together, those figures show that operating resilience was real, but unusually strong investment income made the magnitude harder to treat as a clean run rate. Management raised Healthcare’s full-year floor by just $25M, to at least $4.55B.

PBS commercial momentum remains healthy; the economics remain under pressure

PBS itself remained the unresolved piece. The segment decline was planned, reflecting large-client renewals and extensions plus investment in Signature. However, PBS tracked modestly below management’s earlier assumptions because GLP-1 growth moderated and some economics moved into Specialty. Evernorth still beat quarterly consensus by about $37M, yet management left its full-year adjusted-income floor unchanged at $6.9 billion and said lower GLP-1 volumes would offset the second-quarter favorability in the back half.

While PBS earnings remain under near-term pressure, retention rates and other forward indicators still appear to be healthy. PBS retention remains above 97% for 2026, preliminary 2027 retention is mid-90s or better, and secured 2027 new business exceeds the prior two selling seasons combined. Cigna plans to move its insured book to Signature in 2027 and at least half of Evernorth PBS members by year-end 2028. Again, this argues for a healthy to strong selling season and retention, but investors will still need to see real stability in the underlying margins and economics before underwriting CI’s long-term targets. Some of that will only come with time.

The market still demands proof

Estimate revisions were concentrated in 2026. CI’s 2026 consensus EPS estimate increased $0.10, from $30.41 on July 29 to $30.51 on August 20, matching the guidance raise. The 2027 estimate was effectively unchanged at $33.47, versus $33.48 before the print. Current estimates imply 9.7% growth in 2027, just below the 10% lower bound of management’s long-term algorithm; using the $30.45 guidance floor as the base produces 9.9%. Analysts incorporated the higher 2026 floor without increasing absolute EPS expectations for 2027.

^{Source: Koyfin; CI 2024 Investor Day; Graver Research calculations. Data through August 20, 2026.}

The stock reaction has been negative, although the entire move since the report should not be attributed to just earnings. CI fell 3.0% on July 30 and declined 7.4% from the July 29 preprint close through August 20, while the S&P 500 gained 4.4% and XLV gained 3.7%. The setup had not been especially demanding versus healthcare: from April 29 through July 29, CI rose only 1.4% while XLV gained 16.4%. CI currently trades at 8.7x NTM earnings, below both its 11.0x 10-year median and its 9.2x negative-one-standard-deviation band. At this valuation, investors do not need a flawless story, but they still need a credible 2027 bridge.

What matters from here

The next thesis-defining event is the September 30 Investor Day. Management needs to show a 2027 bridge in which normalized Specialty growth and continued Healthcare gains more than offset remaining PBS pressure, Signature investment and ACA-exit friction. Formal segment guidance on the fourth-quarter call will be the next confirmation. Evidence of profitable Signature commitments, pricing that keeps pace with elevated medical trend, and FY27 implied EPS growth moving above the 10% low end of the algorithm would strengthen the case. An Evernorth guide cut, continued PBS shortfalls, faster Specialty normalization, worsening Healthcare trend or greater dependence on investment income and buybacks would weaken it. The second quarter established that Cigna’s portfolio can protect earnings while one business resets. The next step is proving that the same portfolio can produce additive growth after the easiest offsets normalize.

Subscribe now

It did not settle the longer-term debate. Marketplace, Medicare and expense execution produced most of the upside, while Medicaid performed to plan without improving its full-year HBR outlook. That distinction matters after CNC shares rose 47.3% from April 27 through July 27, well ahead of the S&P 500 and XLV. Investors were already paying for a 2026 repair. The question now is whether recurring earnings can grow into 2027 without a faster Medicaid turn.

The beat was real and 2026 is largely settled

The headline revenue beat was less impressive than the earnings result. Total revenue of $53.6B exceeded consensus by $5.9B, but $4.9B, or 83%, of that surprise was premium-tax pass-through. Premium and service revenue of $44.4B still beat the $43.3B hurdle by $1.1B. More importantly, the operating ratios easily cleared the consensus hurdle: HBR of 89.6% was 160 basis points better than consensus, and adjusted SG&A of 6.9% was 30 basis points better.

The new guidance puts much firmer bounds around 2026, but it does not establish a normal earnings base for 2027+. The HBR range improved 40 basis points at the midpoint to 90.5%–91.3%, while the adjusted SG&A range improved 10 basis points to 6.9%–7.5%. Subtracting the $0.50 settlement benefit leaves a simple normalized EPS floor of greater than approximately $4.30, still 22% above the $3.52 consensus entering the report. First-half adjusted EPS was $5.88, but management expects only a little above breakeven in the third quarter and a fourth-quarter loss because of PDP and Commercial seasonality. The first half is not a run rate.

^{Sources: Centene; StreetAccount; Koyfin; Graver Research calculations.}

Commercial and Medicare drove the reset

Marketplace was the largest source of improvement. Commercial HBR fell to 79.2% in 2Q26 from 90.6% in 2Q25. Separately, management raised its FY26 Marketplace pretax-margin outlook to 4.5%–5.0% from the 3% view provided after 1Q26. Approximately $180 million of final 2025 risk-adjustment favorability contributed about 60 basis points of full-year margin, but it did not explain all of the increase. June Wakely claims data supported management’s view of relative acuity, while medical cost developed better than the conservative assumptions adopted after 1Q. The remaining caution is that 2026 risk adjustment is still an estimate and Marketplace membership has continued to decline.

Medicare and SG&A made the reset broader. Medicare HBR improved to 89.5% in 2Q26 from 90.9% in 2Q25; PDP margin is now expected above 3% versus the initial 2%; and MA is approaching breakeven this year. Adjusted SG&A also beat consensus. These are real positives, but Medicare included approximately $160 million of favorable prior-year settlements, and CNC recorded no 2026 MA premium deficiency reserve after establishing $389 million by 2Q25. Commercial and Medicare are carrying more of the near-term recovery, but the quarter is not a clean run rate.

Better Medicaid rates were absorbed by worse attrition

Medicaid was stable, not weak. Its 93.9% 2Q26 HBR improved 100 basis points year over year and was in line with management’s forecast. The composite rate outlook increased to approximately 5.0% from 4.5%, modestly above the mid-4% fundamental trend. However, expected year-end membership attrition worsened to 8%–9% from approximately 6%. Management therefore held the incremental 50 basis points of rate favorability against the acuity effect of losing more members, leaving the full-year HBR outlook around 93.5%. That is a reasonable forecast posture, but it also means better rates did not translate to visible margin upside.

^{Source: Centene.}

That unchanged HBR matters because Medicaid remains CNC’s largest identified long-term earnings lever. The current 93.5% outlook is roughly 350 basis points above the approximately 90% normalization marker used at the December 2024 Investor Day, where management associated the gap with $1.60–$2.00 of adjusted EPS opportunity. That sensitivity is stale and predates the 2025 earnings collapse, but it’s still useful for understanding the scale. Management now expects OB3-related eligibility pressure to mute the recovery through part of 2027, with acceleration more likely in the second half as rates catch up.

Membership mix adds to the timing risk. Expansion members were approximately 19% of the Medicaid book in 2Q and are expected to be about 18% at year-end. Management cited external estimates suggesting 25%–40% of that cohort could roll off over 2027–2029, equivalent to roughly 4.5%–7.2% of total membership using the expected year-end mix. Peers show the same rate-versus-cost problem: ELV kept its approximately negative 1.75% Medicaid margin outlook despite better rates, while MOH still expects 4% rates against 5% trend. The sector appears closer to stabilization than normalization.

The Street agrees on little beyond 2026

Consensus has adjusted accordingly. FY26 EPS increased to $4.89 on August 16 from $3.52 on July 27, while FY27 rose to $5.32 from $4.48. The current FY26 range is narrow at $4.80–$5.09 across 20 analysts; the FY27 range is much wider at $4.61–$6.25 across 21. Reported-base growth from the FY26 average is only 8.8%, but subtracting management’s $0.50 nonrecurring item from the current consensus creates a simple $4.39 normalized reference and raises implied FY27 growth to 21.2%. That simple normalization shows why the 2027 debate remains open.

^{Source: Koyfin; Graver Research calculations.}

The stock has not rejected the print, but it has not fully reflected the estimate reset either. CNC rose 5.3% from July 27 through August 14, roughly matching the S&P 500’s 5.0% gain and beating XLV’s 2.4%, while FY27 consensus increased 18.8%. The implied FY27 P/E fell to 12.7x from 14.3x. On the separate NTM measure, CNC trades at 14.4x versus a 13.2x 10-year median, while its relative multiple to the S&P 500 is in line with history. Valuation is not demanding on the new FY27 number, but it is no longer distressed enough to make the timing of Medicaid recovery irrelevant.

What matters from here

The next tests are more specific than another quarterly EPS beat. Medicaid HBR needs to improve from the roughly 93.5% path as the July 1 rate cohort matures, even if membership reaches the 8%–9% attrition range. January 2027 rates must recognize current acuity and OB3, while the Marketplace risk-adjustment accrual needs to hold as more claims data arrive. PDP margin also needs to remain above 3% without another prior-year settlement. Management’s 2026-to-2027 bridge must then show how recurring gains offset the $0.50 that falls away.

CNC has earned a higher 2026 base and more benefit of the doubt on execution. It has not earned a straight-line extrapolation into normalized earnings. A Medicaid HBR below the current path, stronger January rate support and a clean recurring bridge would strengthen the case. More attrition-driven acuity pressure or a reversal in Marketplace risk adjustment would weaken it. For now, 2026 is largely settled. Whether rates can finally convert into Medicaid margin remains the thesis-defining question.

Subscribe now

That said, the lackluster stock reaction to the quarter was consistent with the large hurdle created by the run-up in the stock since the 1Q26 report. From the April 28 pre-1Q close through July 28, Humana shares increased 69.2%, while Bloomberg 2027 adjusted EPS consensus increased only 7.1%. The stock declined 6.0% on the report, a reaction consistent with a higher expectations bar rather than a weak quarter. By August 7, it had recovered to $385, only 1.0% below the pre-print close, while consensus was another 1.6% higher. In other words, the market largely retained the recovery narrative after the initial reset.

The headline “beat” looks more “in-line” with context

Adjusted EPS of $7.61 beat FactSet consensus by 5%, and full-year EPS guidance of “at least” $9.00 was reaffirmed. Overall, this was a decent enough quarter to keep the recovery story on track for now, but not enough to assume any near-term upside to management’s targets. The underlying drivers of the quarter’s 5% EPS beat were also modestly less impressive than the headline suggests. HUM’s 91.1% consolidated MLR was directly in-line with consensus, while the 91.2% Insurance segment MLR missed consensus by 16 bps. It is important to note that the Insurance segment MLR was in line with management’s qualitative guidance of “slightly above 91%.” The $7.61 2Q26 EPS was also in line with management’s guidance that 80-85% of full-year EPS would fall in the quarter.

The profile of the 5% EPS beat was more consistent with modest overall revenue upside than with a true margin-driven operating beat—the latter would have been more supportive of the stock here. Similar to EPS, adjusted pretax income beat consensus by approximately 5%. Revenue and medical membership were 0.7% and 0.9% above consensus, respectively. However, the adjusted operating cost ratio was 20 bps worse than consensus. That context around the underlying drivers and reaffirmed EPS guidance moves the takeaway for the quarter to more “in-line” than the headline suggested.

The read on reserve quality also appears to support the “in-line” read of 2Q26—i.e., reserves appear healthy, but there is nothing to suggest they are incredibly conservative or leaving them a substantial cushion for future quarters. Favorable 2Q26 prior-period development declined to $53M from $161M a year ago. IBNR remained at approximately $8.9B at quarter-end, up from $7.0B a year ago and roughly flat sequentially after the substantial 1Q26 build. The quarter’s results were not driven by an unusually large reserve release, suggesting that underlying operations/trends were likely as they appear in the results. Operating cash flow also benefitted from the IBNR build and the timing of a $1.05B Medicaid state-directed payment that settled shortly after the quarter ended. All in, the quarter reduced near-term downside risk, but it did not yet establish a broader earnings inflection.

Again, the unchanged “at least” $9.00 2026 EPS guidance reinforces that distinction. Bloomberg 2026 adjusted EPS consensus was $9.10 as of August 8, essentially unchanged from $9.11 on July 28. Year-to-date adjusted EPS is already $17.91. Management expects an adjusted loss of approximately $1.00 per share in 3Q26. Bloomberg 3Q26 adjusted EPS consensus was a $1.02 loss as of August 8, closely matching management’s approximately $1.00 loss expectation. If full year adjusted EPS were to finish exactly at $9.00, then the implied 2H26 result is a loss of $8.91 per share. That highlights how little the 2Q26 print generally can serve as a conventional earnings run rate. The print therefore did more to validate the 2026 floor, than it did to raise the 2026 ceiling—which, to be clear, should be good enough to sustain the stock at this point in their recovery.

^{Sources: Humana; StreetAccount; Bloomberg; Graver Research analysis. Consensus providers and contributor counts vary by metric.}

The growth-to-margin handoff is now the core HUM debate

Individual MA membership reached 6.454M at June 30, an increase of approximately 1.204M, or 23%, from year-end 2025 and still tracking toward roughly 25% full-year growth. Through the limited claims window available, management said cost trends for both new and existing members were in line with the planned 7%-8% all-in medical and pharmacy range, with overall performance toward the better end. New-member engagement was in line with, and on some measures better than, renewing-member engagement; dual-eligible performance was also consistent with the rest of the book. That is meaningful given the size and speed of the enrollment increase. However, the favorability assessment was based on only about four months of completed claims, and Humana did not disclose a cohort-level benefit ratio, margin, or reserve position.

The year-two margin logic itself is reasonable. Retained members should benefit from better diagnosis and payment alignment, deeper care-management engagement, and lower acquisition and onboarding costs. Management said the all-in marketing, acquisition, co-op and onboarding expense for a first-year member is approximately twice the year-two amount. The entering cohort also had characteristics that should help: in March, management said approximately 70% of new members were switchers, approximately 70% were enrolled in four-star-or-better contracts, and roughly 75% came through more attractive channels. Still, these are mechanisms and mix attributes, not a quantified earnings bridge. Humana has not disclosed the retained-cohort denominator, per-member cost reduction, risk-score improvement, or basis-point margin benefit.

The 2027 bid cycle is where that bridge becomes more difficult. Humana is exiting plans that affect approximately 600,000 members and expects to recapture just over 40%, similar to its experience in 2025. At exactly 40%, 360,000 affected members would not be recaptured; management’s “just over 40%” expectation implies a modestly lower residual. Humana also did not disclose how much the exit pool overlaps with the 2026 growth cohort. The central tension is that the benefit changes and exits intended to repair margin could interfere with retaining the members expected to produce the year-two lift. Management expects meaningful 2027 margin progress, but repeatedly declined to quantify it because final membership size and mix remain uncertain.

^{Sources: Humana 2Q26 earnings release and earnings call; Graver Research analysis.}

Expectations already require an Insurance-led recovery

Post-print consensus as of August 8 leaves little ambiguity about where the recovery must come from. Bloomberg adjusted EPS consensus increases from $9.10 in 2026 to $16.34 in 2027 and $27.27 in 2028. The nearly 80% increase expected in 2027 comes with only 3.0% revenue growth. Over the same period, Insurance operating income rises from approximately $170M in 2026 to $1.46B in 2027 and $3.03B in 2028, while CenterWell increases much more modestly from $1.61B to $1.73B and $1.86B. The direction is clear: top-line growth and CenterWell cannot carry the modeled earnings recovery. Insurance execution has to do the work.

At the August 7 close of $385, Humana traded at approximately 23.6x 2027 Bloomberg consensus EPS and 14.1x 2028. That relationship reflects the scale of the expected earnings recovery rather than, by itself, proving the stock is expensive. It also creates a demanding proof requirement. The 2027 EPS estimate range remains unusually wide at $10.39-$20.75, and the stock has already recovered nearly all of its initial post-print decline. With the 2026 floor better supported, incremental equity value increasingly depends on evidence that Humana can reach its at-least-3% sustainable 2028 pretax-margin objective. The 2Q result improved the probability of that outcome at the margin, but it did not establish it.

^{Source: Bloomberg; Graver Research analysis.}

What matters from here

The next tests are more specific than another quarterly EPS beat. Medical-cost trend and reserve development must remain stable through the seasonally difficult second half; the final 2027 benefits and exits must preserve an economically attractive mix; and AEP must show that Humana can retain enough of the 2026 growth cohort and recapture enough of the exit-affected membership to realize the expected year-two benefits. Final CMS Stars data and Humana’s December 10 investor update should also provide better evidence on benefit-year 2028 economics, preliminary 2027 membership and the path toward Insurance margin recovery.

For now, 2Q26 supports greater confidence in 2026 delivery without transferring that confidence into 2027-28. Stable trend, stronger-than-feared retention and a quantified Insurance margin bridge would strengthen the recovery case. Worse exit-related attrition, weaker mix, adverse reserve development or a disappointing Stars outcome would weaken it. The quarter indicated that the current growth cohort has not broken the near-term model. Whether Humana can keep enough of that cohort, and earn an adequate margin on it, remains the thesis-defining question.

UHS: Mixed 2Q26 Results and a Guidance Reset

UHS reported consolidated revenue of $4.638B, +8.3% y/y and 1.3% above StreetAccount (SA) consensus. Adjusted EBITDA net of NCI was $677.9M, +5.4% y/y, but missed SA consensus by 0.5%. Adjusted EPS of $5.98 beat SA consensus modestly by 0.7%. Several specific or unusual—but not necessarily nonrecurring—items affected the quarter: (1) a $100M out-of-period Florida DPP benefit that had been quantified before the print and therefore was not a new investor surprise; and (2) a $28M professional/general liability reserve increase. 2Q25 also included ~$101M of incremental supplemental reimbursements. Comparable segment operations did not contract: same-facility acute-care and behavioral-health EBITDA excluding out-of-period benefits increased 6.3% and 5.7% y/y, respectively. However, excluding the Florida benefit, adjusted EBITDA net of NCI missed UHS’s internal expectations by ~$63M, reflecting $28M of liability expense, ~$20M from Laurel Ridge and ~$15M from Cedar Hill.

UHS reduced the adjusted EBITDA net-of-NCI guidance midpoint by $51.5M, or 1.9%; the adjusted EPS midpoint fell 2.6%, while the revenue midpoint increased 0.2%. The implied full-year adjusted EBITDA net-of-NCI margin midpoint fell ~30 bps, nearly identical to HCA’s ~32-bp reduction. At a high level, two major updates bridged prior guidance to the revised outlook: (1) approximately $150M of incremental Medicaid supplemental benefits; and (2) approximately $200M of new adverse items. Those adverse items included $50M from the Laurel Ridge/San Antonio behavioral-health facility, ~$30M from the reduced Cedar Hill/Palm Beach de novo tailwind, ~$50M of higher liability expense and ~$50M from lower same-facility volume assumptions and other changes. The HIX headwind also increased ~$10M to ~$85M, although management did not specify whether that amount was included in the final ~$50M bucket. Management’s disclosed adverse-item buckets do not fully reconcile to the rounded ~$200M total.

At the midpoint, guidance implies 2H26 revenue growth of 5.8%, a 0.9% decline in adjusted EBITDA net of NCI and ~94 bps of margin contraction, all y/y. That is weak reported EBITDA conversion, but supplemental-payment timing, Laurel Ridge and de novo economics distort the comparison. Management also expects support from new acute-care capacity, Cedar Hill improvement and moderating behavioral-health labor growth; the implied decline therefore is not a clean measure of underlying same-facility earnings.

UHS Lowers Volume Guidance; Mix Pressure Shows Across All Three

Aggregate patient traffic held up in the quarter: UHS same-facility acute-care adjusted admissions increased 2.9% y/y, versus comparable HCA and THC measures of 2.7% and 2.6%, respectively. ED visits increased 4.0% at UHS and 3.6% at HCA on a same-facility basis, and 2.0% at THC on a same-hospital basis. However, UHS reduced its full-year acute-care adjusted-admissions range to 1.5%–2.5% from 2.0%–3.0%, while 1H26 same-facility growth was only 1.4%.

HIX volume and migration patterns were broadly similar and clearly worsened payer mix, but the companies did not identify one common cause of weaker procedure mix. Company-reported UHS HIX volume declined ~15% y/y, versus comparable declines of ~15% at HCA and 13.5% at THC. All three also characterized close to one-for-one migration to uninsured or self-pay. To be clear, these disclosures are not fully comparable or standardized patient-level cohort studies. The narrow conclusion is that lost exchange coverage changed the payer category attached to encounters more than aggregate traffic, while worsening the economics.

Lower surgery volumes and higher professional fees also weighed on the quarter’s results for all three. Same-facility acute-care total surgery declined 0.8% at UHS, versus a 0.7% same-hospital decline at THC and a Graver Research-derived 3.0% same-facility decline at HCA. UHS said inpatient surgery increased and outpatient surgery declined slightly; THC reported inpatient surgery down 1.9% and outpatient surgery up 0.2%; HCA was again the negative outlier, with inpatient and outpatient surgery down 2.3% and 3.4%, respectively. Sequentially, HCA’s total y/y trend deteriorated approximately 190 bps, while THC improved 20 bps, and UHS reported qualitative improvement. Professional-fee pressure remained elevated: UHS said the 7%–9% annual increase embedded in guidance was consistent with its 2026 experience, while HCA reported 8.5% same-facility growth and THC reported ~10%.

Exhibit 1: Comparable-Location Patient Traffic Held, but Mix Deteriorated

HCA and UHS Guidance Bridges Differ Despite Similar Midpoint Cuts

HCA reduced its adjusted EBITDA guidance midpoint from $16.00B to $15.75B, or 1.6%, while UHS lowered its adjusted EBITDA net-of-NCI midpoint from $2.715B to $2.664B, or 1.9%. The implied full-year margin midpoints fell ~32 bps and ~30 bps, respectively. This changes our initial post-HCA/THC conclusion that HCA’s reset was ‘not inevitable.’ The fuller picture is that hospital pressures are real and still developing, but THC’s multi-year Hospital margin expansion story and likely greater initial guidance cushion allowed it to more than absorb them, while HCA and UHS had to reset.

The similar headline cuts came from meaningfully different bridges. UHS added ~$150M of supplemental-payment benefits against ~$200M of facility, liability, volume and other pressure. HCA’s HIX-headwind midpoint worsened by ~$350M while its supplemental-payment midpoint improved by ~$550M; despite that net $200M benefit, EBITDA guidance still fell $250M, implying a residual ~$450M of other adverse revisions. That residual is derived, not management disclosed, but reinforces that HCA’s reset was broader than HIX alone.

Exhibit 2: HCA and UHS Reset ~2%; THC Raised Guidance on Hospital Outperformance and Supplemental Payments

Panel A: Guidance Midpoint Changes

Panel B: Approximate Guidance Bridges

Actual HIX attrition was not meaningfully different across the group, but initial assumptions were. UHS entered the year assuming exchange volume would decline >25%; the actual 1H26 decline was smaller. It did assume 10%–20% of affected patients would find other commercial coverage, which did not materialize, but the worse migration outcome in 2Q26 only increased the projected FY26 headwind by $10M to ~$85M. HCA correctly forecast 15%–20% attrition, but assumed 15%–20% of affected patients would migrate to employer coverage and utilization among those becoming uninsured would fall ~30%. Neither occurred, driving HCA’s much larger HIX reset. THC characterized both the exchange decline and uninsured conversion as roughly in line with its planning assumptions. The distinction is that UHS was more conservative on the volume decline, HCA was right on attrition but wrong on post-coverage behavior, and THC appears to have had both adequate assumptions and enough cushion.

HIX assumptions explain part of the difference, but margin runway and available offsets are what separate THC from the pack. HCA entered 2026 with a more mature margin base: FY25 adjusted EBITDA margin was 20.6%, up ~90 bps y/y, leaving less obvious incremental cost and margin-recovery runway. That does not mean HCA is fully optimized or cannot drive additional efficiencies, but the starting point matters. UHS is harder to characterize. Same-facility EBITDA growth remained positive, but its guide cut reflected a combination of facility-specific issues, liability pressure and lower volume assumptions; there is not enough evidence to describe UHS as either fully optimized or on a THC-like recovery path. THC’s raise was overwhelmingly a Hospital-segment event: Hospital adjusted EBITDA guidance increased $285M versus only $10M for USPI. However, ~$140M of the total $295M raise came from supplemental payments, with the balance reflecting 1H outperformance and better 2H operating assumptions. USPI remains a structural portfolio advantage, but it was not the principal driver of the FY26 raise.

Expectations Explain the Reaction

UHS opened ~6% below the prior close before reversing to finish up 4.3%, an ~11% open-to-close swing. HCA and THC also closed up 7.3% and 7.8%, respectively. By no means does that rally mean that sector pressures went away. Expectations were particularly low for UHS with the stock entering the print at 5.6x NTM EBITDA, near a 10-year low and well below its 8.2x median. UHS avoided another outsized HIX reset, and same-facility segment EBITDA growth remained positive. Expectations and valuation gave investors room to look through a modest miss/guide cut and distinguish company-specific UHS problems from a new sector-wide traffic shock. Using distinct pre-earnings baselines, HCA FY26/FY27 EBITDA consensus has declined 1.4%/2.5% since July 13, while THC FY26/FY27 EBITDA consensus has increased 4.6%/2.7% since July 22.

What Matters Next

What matters next is less about whether the 2Q26 pressures were real—UHS now confirms that they were—and more about how they develop from here. The key questions are whether uninsured patients sustain comparable acuity and procedure intensity, what hospitals ultimately collect on those encounters, and whether surgical weakness stabilizes or expands beyond exchange-affected markets. We also need to monitor whether professional-fee inflation and UHS liability expense remain elevated, whether HCA and UHS can deliver their implied 2H26 outlooks, and whether THC can sustain Hospital margin improvement as supplemental-payment benefits normalize. 2Q26 established that the hospital pressures are sector-wide and earnings-relevant. The remaining debate is which operators still have enough pricing, cost, reimbursement and margin runway to absorb them.

In the quarter specifically, it’s important to note that HCA’s $4.027B adjusted EBITDA included a $543M Florida Medicaid directed-payment program (DPP) benefit. $423M of that benefit was related to pre-2026 periods. Deducting the full $423M pre-2026 benefit would reduce adjusted EBITDA to $3.604B, nearly 9% below pre-print FactSet consensus. This is a one-sided sensitivity, not a clean normalized comparison.

THC experienced similar patient migration from HIX to uninsured in its quarter. It also experienced similar inpatient surgery case softness and professional fee pressure, but was able to raise 2026 adjusted EBITDA guidance. The takeaway for HCA is that the pressures it felt are at least partly industry-wide, but the resulting EBITDA guidance cut was not necessarily inevitable.

HCA called volumes correctly, but got the economics wrong

HCA initially assumed 15%–20% HIX volume attrition for 2026. Of that 15%–20% decline, management further assumed that 15%–20% of affected patients would migrate into employer-sponsored insurance coverage, where hospital economics are generally most favorable, including relative to HIX. HCA also assumed the remainder of affected patients would become uninsured, and that uninsured utilization would fall approximately 30%. Ultimately, HCA estimated that these assumptions would result in a $600M–$900M FY26 HIX headwind, which it intended to partly offset with a $400M “resiliency contribution” (i.e., an enterprise-wide efficiency program). HCA management continued to express confidence in this original framework at multiple intra-quarter conferences all the way through May.

Same-facility HIX equivalent admissions ultimately declined 15% y/y, which was within HCA’s original 15%–20% range. However, the migration of those patients was nearly one-for-one into uninsured (i.e. not 15%–20% into employer-sponsored) and the anticipated utilization reduction did not occur (i.e. not a 30% decline). In total, HCA estimated a $400M 2Q26 HIX headwind inclusive of a $75M upward revision to its original 1Q26 headwind estimate. Graver Research estimates this implies HIX headwinds of $225M in 1Q26 and $325M in 2Q26, or $550M for 1H26—approximately 61%–92% of HCA’s original full-year estimate. As a result, management increased its FY26 HIX headwind estimate from $600M–$900M to $1.0B–$1.2B. At the midpoint, the 2H26 headwind is roughly equal to 1H26, while the implied 3Q26/4Q26 quarterly amount is modestly below 2Q26; at the high end, it equals 2Q26.

Again, it’s important to make the distinction that this reset was principally a coverage-economics miss, and not evidence that patient demand has disappeared. HCA’s admissions, equivalent admissions, and ER visits all strengthened in the quarter. Commercial equivalent admissions excluding HIX also grew 2.4% in the quarter. Still, the HIX migration is not the sole explanation for HCA’s weaker underlying performance as inpatient and outpatient surgeries declined 2.3% and 3.4% in the quarter, respectively. On the call, HCA management acknowledged broader affordability pressure on elective procedures and said HIX was a ‘big piece’ of the surgery declines, but could not quantify the relative contributions despite repeated analyst questions.

Exhibit 1: HCA’s Original 2026 Exchange Assumptions Versus the 2Q26 Update

Weaker 2H26 implied guidance is now the core HCA debate

With the 2Q26 report HCA tightened its adjusted EBITDA guidance range by $200M and lowered the midpoint by $250M, or 1.6%. The revenue guidance range was tightened by $1B, but the midpoint remained unchanged, resulting in an approximately 32 bps decline in the adjusted EBITDA margin midpoint. Diluted EPS guidance is now $0.70, or 2.3%, lower at the midpoint. For the full year, the adjustment points to lower earnings conversion rather than lower revenue expectations. When isolating for the implied 2H26 guidance revenue and EBITDA performance starts to look weaker - more on that later.

The 2Q26 call provided some important details underlying the headline revenue and adjusted EBITDA guidance range revisions. The revised HIX headwind assumption is ~$350M worse at the midpoint, while the assumption for Medicaid supplemental payments improved by ~$550M. The net of those two changes produces a $200M benefit; however, the adjusted EBITDA midpoint was lowered by $250M. This implies another ~$450M of residual headwinds for the full year. Management described that residual as roughly $500M of broader growth moderation but did not decompose it despite a direct analyst question. Surgical mix, professional fees and weaker operating leverage are plausible contributors; whether the full $400M resiliency contribution remains intact is an open question.

1H26 adjusted EBITDA totaled $7.829B on revenue of $39.339B. The revised guidance midpoints therefore imply $7.921B of 2H26 adjusted EBITDA on $38.911B of revenue. That implies particularly weak revenue and EBITDA performance in the back half of this year and will start to raise questions about 2027 performance. Excluding 2020–2021, 2H revenue has exceeded 1H in every year since 2015. Reported 2H26 revenue would be the first exception, declining 1.1% versus 1H26; however, 1H26 includes $980M of revenue attributable to pre-2026 Florida program periods. The midpoint also implies 2H26 y/y revenue growth of just 0.6%, a nearly 600 bps slowdown vs the 6.5% 1H26 revenue growth performance. At the midpoint 2H26 adjusted EBITDA is expected to fall 0.8% y/y. On a reported basis, guidance surprisingly implies 1.2% adjusted EBITDA growth and 46 bps of margin expansion in 2H26 versus 1H26. Excluding 2020–2021, 2H adjusted EBITDA margins have declined by an average 16 bps versus 1H since 2015, although the Florida catch-up distorts the 2026 sequential comparison. That discrepancy will create questions for investors. HCA management is strong, but has it provided enough cushion in the new guidance to avoid another cut?

Exhibit 2: HCA’s Implied 2H26 Guidance Requires Margin Expansion Despite a Sequential Revenue Decline

How the Florida Medicaid program impacted the quarter

Turning to the 2Q26 performance specifically, revenue was $20.230B up 8.7% y/y. Adjusted EBITDA was $4.027B, up 4.6% y/y, while margin declined 78 bps to 19.9%. Revenue and EBITDA beat pre-print consensus estimates by 3.9% and 1.9% respectively, which was already known from the July 14 preliminary update. Adjusted EPS increased 11% y/y while adjusted net income only increased 2.1%, with the share count decline providing substantial support.

The quarter’s reported performance was supported by HCA’s recognition of $1.372B of Florida program revenue. That included $829M of related program expenses, resulting in a $543M adjusted EBITDA benefit for the quarter. Of the totals recognized, $980M, or 71%, of revenue and $423M, or 78%, of the net benefit were related to pre-2026 periods. It’s important to note that the program is a core and ongoing part of its business, and what is being highlighted here is just the period-attribution and catch-up timing. That said, these sort of out-of-period payments can be common with state Medicaid supplemental payment programs which have grown significantly in recent years as a whole and as a percentage of hospital reimbursement. As these programs have grown, it has made isolating pure in-quarter performance and y/y compares more difficult.

Even so, creating sensitivities around performance by removing the out-of-period portions of these payments is still a useful exercise. Removing only the pre-2026 net benefit of $423M produces approximately $3.604B of 2Q26 EBITDA, an 18.7% margin, and a 6.4% y/y EBITDA decline. Mechanically allocating the full $980M to same-facility revenue would lower revenue per equivalent admission growth from 6.4% to approximately 1.2%; however, HCA did not disclose the precise same-facility allocation. To be clear, these calculations are not “normalizations,” but sensitivities. A full normalization would also require adjusting 2Q25 for unquantified retrospective Medicaid supplemental-payment benefits and accrual timing, which cannot be done cleanly given current disclosures. However, we can conclude that while the headline figures for the quarter overstate momentum, the sensitivity analysis performed here also does not establish a precise normalized underlying growth rate– the truth likely lies somewhere in between.

Exhibit 3: Most of Florida’s 2Q26 Benefit Was Related to Prior Periods

Panel A: Florida program recognition recorded in 2Q26

Panel B: Pre-period-excluded 2Q26 sensitivity

Volumes held up, but worse mix negatively impacted earnings

2Q26 same-facility admissions grew 2.5%, equivalent admissions grew 2.7%, and ER visits grew 3.6%. That represents acceleration from 0.9%, 1.3%, and 0.3% in 1Q26, respectively. Commercial equivalent admissions excluding exchanges also increased 2.4% in the quarter. All of this supports HCA’s claim that demand remains healthy at a broad level.

The issue is that, within that broader demand, the underlying mix of services has weakened. Same-facility inpatient surgery cases declined 2.3%, and outpatient surgery cases declined 3.4%. Surgery cases are generally one of, if not the, most important revenue and profit drivers for hospitals, so the decline is an important trend to monitor. Looking deeper, 1H26 elective inpatient surgery cases fell approximately 6%, while emergent surgery cases increased 2%. Roughly 90% of outpatient surgery cases are elective. Management said lost exchange volume was a ‘big piece’ of the surgery weakness but could not separate it from broader affordability pressure.

As stated previously, HIX equivalent admissions declined 15% while uninsured volumes increased by approximately 15%. Uninsured patients now represent more than 10% of equivalent admissions, compared to 6.8% for HIX patients. That one-for-one patient switch at similar service levels creates substantially worse reimbursement and collection economics for HCA. Contracted rate and government update benefits helped offset some of that pressure, but again the Florida program accounting obscures reported revenue intensity.

When considering Medicaid supplemental-payment programs, management said same-facility cost per equivalent admission was approximately flat y/y and improved 1.4% sequentially. Salary and supply growth remained controlled, however professional fees, which reside in the other operating expense line item, increased 8.5%. That increase was primarily led by anesthesia and radiology, after roughly 10% 1H26 growth. Core labor and supply trends were controlled, but mix and professional fees limited operating leverage in the quarter and first half of the year.

THC confirms the mix pressures, but had more cushion and levers to pull

THC reported same-hospital admissions growth of 2.3% and adjusted admissions growth of 2.6%. Management also said Hospital-segment HIX admissions declined 13.5%, with approximately 80%–100% of the lost volume migrating to uninsured. Same-hospital inpatient surgery cases fell 1.9% and it also saw professional fees increase approximately 10%. THC corroborated the principal demand, coverage/mix dynamics, and cost pressures described by HCA, but the EBITDA performance at least versus consensus expectations and prior guidance was materially better.

THC reported 16.3% consolidated EBITDA growth and 22.3% hospital-segment EBITDA growth, with hospital margin expanding 240 bps y/y. It also raised EBITDA guidance by $295M at the midpoint. Even after deducting the full $92M prior-period Medicaid benefit, THC’s adjusted EBITDA would remain approximately 6.3% above consensus and 8.1% above reported 2Q25. That is all in stark contrast to HCA’s $250M reduction to its EBITDA guidance at the midpoint.

To be fair to HCA, THC has significant exposure to USPI, its ASC business, different geographies, and different exchange concentration. It also uses different definitions for key items and different Medicaid accounting. The real conclusion here is that the hospital environment alone did not dictate HCA’s outcome, but its exposures, starting assumptions, service mix, and expense conversion mattered greatly.

Exhibit 4: HCA and THC 2Q26 Operating Comparison

What matters from here

HCA closed July 24 up 1.5%, but still down 2.2% since just before the preliminary update and guidance cut were announced on July 14. The final figures in the report matched the preliminary update. The one-day positive move with the full report on July 24 likely came from a mix of relief that no further cut emerged, improved clarity on the moving pieces, and potentially some THC sympathy.

What matters most from here is: gaining a better understanding of the composition of the $450M–$500M residual reduction to EBITDA guidance; whether the $400M resiliency contribution remains intact; HIX and uninsured mix and service intensity/utilization; progression of elective surgery cases; and evidence supporting 4Q26 growth over 3Q26 and the right 2027 exit rate or jump-off. Further 2027 exchange attrition and potential impacts of Medicaid work requirements will also start to come into focus as we move through the year. For now, long-term demand appears to remain intact, but near-term confidence in earnings conversion and management’s recovery cadence has weakened.

Subscribe now

On the first debate, the evidence points more toward mix pressure than an outright decline in demand. MOH underestimated the concentration of high-cost members in a deliberately smaller Marketplace book. THC, CYH and DGX indicate that many patients losing exchange coverage continue to use healthcare services, often with a less favorable payer profile. The operating pressure is visible across the system, but the earnings impact and stock reaction depends on each company’s starting assumptions, exposure, pricing, service mix and cost execution.

THC provides the most directly comparable read-through to HCA. Its admissions, uninsured-mix and inpatient-surgery trends closely resembled HCA’s preliminary results, yet Tenet delivered a large underlying beat and raised guidance. The release supports HCA’s account of the operating environment, but it does not support treating HCA’s negative EBITDA reset as the default outcome for the hospital group.

The managed-care signals are more company-specific. MOH’s Medicaid results are most relevant to CNC and broadly consistent with ELV’s outlook: cost pressure remains elevated but stable, and improving 2027 rate support reinforces the case that 2026 marks the margin trough, although neither company has shown that recovery is underway. MOH’s Marketplace miss is a real adverse-selection warning for ELV, but not a direct contradiction of ELV’s 2Q ACA upside. The companies entered the year with different, only partly disclosed earnings baselines, and ELV’s upside was not clean evidence of better current-year claims experience. For UNH, MOH’s improved dual-eligible Medicare performance is directionally consistent with UnitedHealthcare’s stronger 2Q Medicare result. Neither company’s performance, however, establishes a broader MA cost-trend inflection.

On the second debate, MEDP and TMO both reported improving biopharma customer activity. The breadth of TMO’s commentary and the recovery in MEDP’s RFP environment make the external demand setup more constructive for IQV, although neither result provides a reliable point estimate for IQV bookings.

Exhibit 1: The six reports matter most for CNC, HCA and IQV

The reports directly inform three coverage debates; implications for other covered names are narrower or more company-specific

Subscribe now

Coverage attrition is changing who pays—and who remains insured

MOH entered 2026 expecting a sharply smaller but profitable Marketplace business. Average pricing increased approximately 30%, while membership declined 59% year over year to roughly 280,000, and the company targeted an 85.5% MCR and a 1.7% pretax margin. First-quarter performance appeared to validate that setup: the normalized MCR was 79.5% and in line with plan.

Second-quarter claims exposed a flaw in the original assumption. MOH had priced for adverse selection, but the remaining book retained more members with high-cost drugs, oncology care and HIV treatment than expected. Risk adjustment did not fully offset those claims. The company increased its Marketplace MCR outlook ~450 bps to approximately 90% and lowered the segment’s contribution by $1.50 per share, from a $0.75 profit to a $0.75 loss.

The headline loss overstates the current-year deterioration. Management attributed approximately $1.00 per share of the revised $0.75 loss to prior-year items and still expects roughly $0.25 of profit from 2026 activity. Even so, the current-year outlook weakened by approximately $1.00 per share, and MOH plans to reduce the business by another $1 billion in 2027. Its 2026 experience is therefore relevant as an adverse-selection case study, not as a representative industry sample. Management noted that MOH has only about 1% of industry-wide Marketplace enrollment.

ELV’s result does not provide a clean counter-signal. ELV also priced for higher morbidity after the expiration of enhanced subsidies, but it did not disclose a comparable starting MCR or margin. Management said after both the first and second quarters that the risk pool was developing broadly in line with its assumptions. The approximately $0.25 of ACA upside reported in 2Q included bronze-plan seasonality and favorable final 2025 risk adjustment; most of the risk-adjustment benefit was re-established in the 2026 accrual.

The comparison is still useful, but for a narrower reason. MOH shows that large rate actions and deliberate membership contraction do not eliminate selection risk. ELV shows that the financial outcome also depends on what was embedded in the starting forecast. Pricing, geography, metal-tier mix, risk adjustment and the initial morbidity assumption remain critical. Available disclosures do not establish whether MOH’s pressure is sector wide.

Provider results show where some displaced utilization is landing. CYH said most patients who lost exchange coverage continued to use its hospitals as self-pay. Self-pay and uncompensated visits increased from just under 5% to more than 6%, and approximately half of adjusted-admission growth came from uninsured encounters that produced little net revenue. CYH now expects a $50–$75 million full-year HIX-related EBITDA headwind.

DGX saw a similar selection effect without the same collections pressure. The company estimated ACA enrollment had fallen more than 20%, while related requisitions declined only 8%. Tests per requisition rose 6%, leaving test volume down roughly 2% and revenue approximately flat. Patient collections and bad debt remained stable. The patients who retained coverage, or continued to seek testing after losing it, used more diagnostic services per encounter.

These observations support HCA’s explanation that exchange disenrollment increased uninsured utilization and reduced the economics of otherwise healthy patient traffic. They do not imply that all providers face the same earnings pressure. Diagnostics, ambulatory care and acute-care hospitals have different exposure to payer mix, acuity and collection risk.

Medicaid pressure looks stable; recovery still has to be earned

MOH increased its 2026 adjusted EPS floor by $0.25 to $5.25, but the segment bridge was volatile. Medicare improved by $1.50 per share, Medicaid improved by $0.25, and Marketplace deteriorated by $1.50.

Medicaid cost trend remained approximately 5% against roughly 4% rate growth. The second-quarter MCR rose to 92.7% from 92.0% in the first quarter, although management described utilization as high and stable rather than worsening. Behavioral health, specialty pharmacy, outpatient professional services and inpatient care remained the main pressure points. MOH still expects only a 1.2% Medicaid pretax margin in 2026, and approximately 55% of its premium does not reprice until January 1, 2027.

The read-through is most relevant to CNC. Stable utilization and improving state rate actions support the view that 2026 can mark the trough in Medicaid margins. They do not establish an inflection in current profitability. The timing of rate resets, mix of state programs and benefit design make exact MCR comparisons unreliable.

MOH’s experience is also consistent with ELV’s unchanged outlook for an approximately negative 1.75% Medicaid margin. Both companies describe cost pressure as elevated but no longer accelerating, with stronger rate support ahead. Neither has yet produced evidence of a sustained margin recovery.

Medicare was better, but product-specific. MOH lowered expected cost trend in its dual-eligible business to approximately 4% from 6%, supporting $1.50 per share of upside. Traditional MA-PD still represents an estimated $1.00 per-share loss and will be exited. The duals improvement is directionally consistent with UNH’s better Medicare performance. It does not establish a broad utilization inflection for HUM or CVS.

THC confirms HCA’s operating pattern—not its earnings outcome

Tenet and HCA reported strikingly similar hospital volume trends. THC’s same-hospital admissions and adjusted admissions increased 2.3% and 2.6%, respectively, compared with HCA’s 2.5% and 2.7%. Inpatient surgeries fell 1.9% at THC and 2.3% at HCA. Tenet also saw clear coverage pressure: charity and uninsured admissions increased 70 basis points, related visits increased 90 basis points, and its uncompensated-care ratio rose 330 basis points to 29.6%.

The earnings results diverged. THC’s $1.304 billion of adjusted EBITDA exceeded consensus by 14.4%. The quarter included a $92 million favorable Medicaid supplemental-revenue adjustment related to prior years. Removing the full amount leaves approximately $1.212 billion of EBITDA, still 6.3% above consensus and 8.1% above last year. On the same conservative adjustment, hospital margin was approximately 16.2%, about 60 basis points higher year over year.

Tenet increased the midpoint of 2026 EBITDA guidance by $295 million. The bridge included $140 million of incremental Medicaid supplemental revenue, $97 million of first-half outperformance and $58 million of expected second-half improvement. Excluding the supplemental-payment update, the operating outlook improved by $155 million. The new $4.93 billion midpoint stands 6.4% above prior guidance and 5.8% above pre-print consensus.

The contrast with HCA begins with the starting assumptions. Tenet continues to incorporate a $250 million full-year headwind from the expiration of enhanced premium tax credits. HCA raised its estimate of the same broad pressure from $600–$900 million to $1.0–$1.2 billion and lowered its EBITDA midpoint by $250 million. THC therefore does not refute HCA’s payer-mix explanation. It shows that exposure, prior assumptions, pricing, Medicaid supplemental payments and expense execution can lead to different earnings outcomes in a similar volume environment.

Historical comparability also argues for restraint. From 1Q24 through 2Q26, HCA and THC admissions growth had a correlation of approximately 0.71, but equivalent and adjusted admissions correlated only 0.52; sequential direction matched in four of nine comparisons. CYH was directionally similar over the same period, with correlations of approximately 0.69 for admissions and 0.68 for equivalent or adjusted admissions. Those relationships are useful corroboration, not forecasting tools.

CYH’s surgery data deserve even less weight. Definitions have not been consistent enough for a standardized series, and the companies have diverged in prior quarters. CYH’s current 3.8% decline in inpatient surgeries supports the direction of HCA’s reported mix weakness, but it should not be used to estimate HCA’s future volumes or earnings.

Exhibit 2: THC confirms HCA’s operating pressures, but not its earnings outcome

HCA and THC reported nearly identical admissions and inpatient-surgery trends in 2Q26. Tenet’s underlying beat and guidance increase show that similar operating pressures do not produce a uniform earnings outcome.

Panel A: 2Q26 operating and earnings comparison

Panel B: Historical volume comparison

MEDP and TMO improve the demand setup for IQV

MEDP’s net new awards increased 28% to $796 million, producing a 1.13x book-to-bill ratio. RFP activity improved sequentially and year over year, and management described a broader group of recently funded biotechnology customers. That is constructive after an extended period of uneven funding and cautious trial starts.

The quality of the rebound needs qualification. More than half of the sequential improvement in net bookings came from fewer cancellations rather than higher gross awards. Oncology represented more than half of bookings and award notifications, and several large metabolic programs still influence customer concentration. MEDP is also more exposed than IQV to small and mid-sized biotechnology sponsors.

TMO provides the stronger cross-check because PPD (TMO’s CRO subsidiary) has greater large-pharma and global CRO exposure. Pharma and biotechnology organic growth reached the mid-single digits, led in part by clinical research. Management said clinical-research authorizations had been strong for several quarters and typically require about six months to convert into revenue. Improving biotechnology spending is now appearing in reported growth, and TMO modestly raised its second-half organic-growth assumptions.

The combined evidence raises confidence in a firmer clinical-research demand environment into the second half and 2027. It does not justify a specific IQV book-to-bill estimate or a market-share conclusion. MEDP’s sponsor mix differs, while TMO sells PPD as part of a broader integrated offering. The appropriate read-through is improved end-market direction.

The setup into the print is shaping the stock reaction

At this stage, the tape is better read against what each stock had already priced in and the size and quality of the earnings reset. Consensus revisions remain incomplete and are not yet a useful measure.

ELV and MOH show why the setup matters. From the first close after their 1Q results were fully absorbed to the pre-2Q close, the stocks rose 30.0% and 26.9%, respectively. Both companies then beat quarterly EPS and raised FY26 guidance, yet ELV fell 8.5% and MOH declined 9.7% in the first full post-print session. The headline math was positive, but neither result cleared the bar embedded in the stock. ELV did not show that Medicaid margins had begun to recover, while MOH’s Marketplace reset weakened confidence in its forward earnings base.

UNH provides a useful counterpoint. Shares had gained 21.0% since the post-1Q close before the company delivered a roughly 30% adjusted EPS beat and raised guidance to $19.50–$20.00. The stock gained only 1.2% in the first session, although the cumulative move reached 4.3% through July 21. The result was clean, but expectations had already risen materially.

HCA and CYH are more straightforward guidance reactions. HCA had declined 9.6% since its 1Q report, but the preliminary update lowered the FY26 EBITDA midpoint 1.6% and drove another 6.9% decline. CYH entered its report up 18.8%, delivered only a 1.0% EBITDA beat, cut its guidance midpoint 5.5%, and fell 13.7%.

The positive reactions were backed by cleaner earnings resets. MEDP, TMO and DGX gained 14.7%, 8.7% and 8.6%, respectively, after beating the relevant quarterly measure and raising guidance. MEDP’s move was particularly notable after a 34.2% run-up, suggesting the bookings rebound mattered more than the guidance increase alone. THC was the clearest case: adjusted EBITDA exceeded consensus by 14.4% and the new midpoint rose 6.4%, supporting an approximately 14% after-hours gain. The concurrent moves in HCA and UHS indicate that investors viewed part of Tenet’s result as transferable to the hospital group.

Exhibit 3: The stock reaction reflects both the earnings reset and the pre-print setup

The post-1Q return provides context for the expectations embedded in each stock. The first post-print move then shows whether the quarter and revised outlook cleared that bar.

Implications for core coverage

The highest-value read-throughs are concentrated in three names. For CNC, MOH supports a stable Medicaid cost trend and better 2027 rate support, while highlighting the selection risk in a shrinking Marketplace book. For HCA, THC validates the payer- and surgery-mix pressure but makes HCA’s earnings reset look less transferable across the hospital group. For IQV, MEDP and TMO provide the strongest external evidence this quarter that clinical-research demand is improving.

The evidence for the remaining names is narrower. MOH’s duals performance is consistent with UNH’s stronger Medicare result, but does not resolve the broader MA debate for HUM or CVS. ELV’s Marketplace result cannot be compared with MOH’s without accounting for different starting assumptions. The six reports do not materially change the outlook for CI, MCK or COR.

The next useful evidence will come from the HCA and THC calls. The release-level data already establish the operating pattern; management commentary should determine whether the divergence in earnings was driven mainly by exposure and starting assumptions or by a more durable difference in pricing, service mix and expense execution.

The quarter establishes a higher and more credible earnings base. UnitedHealthcare and Optum Health produced roughly 83% of the $1.75 billion consolidated adjusted operating-earnings upside, and both full-year segment guides moved higher. The offset is commercial cost trend modestly above 11%, which extends full commercial margin recovery beyond 2027. Medicare improved materially, but management did not characterize that performance as a broad utilization inflection.

Exhibit 1. 2Q26 at a glance

Subscribe now

The beat survives the harshest reserve adjustment

The full-removal case is intentionally severe. Management said most of the $860 million related to 2026 dates of service, so treating it as a stale prior-year reserve release would be too punitive. The calculation nevertheless provides a useful earnings-quality bookend: it adds the full amount back to reported medical costs and removes the after-tax EPS impact using the updated 18.5% tax rate and 906 million diluted shares.

The operating upside was also broad enough to survive that adjustment. UnitedHealthcare and Optum Health contributed $822 million and $636 million of variance versus Street expectations, respectively. Optum Insight added $213 million and Optum Rx $100 million. Revenue was only 1.1% above consensus and the 12.7% operating cost ratio was in line, making margin execution—not top-line leverage—the principal source of upside.

Exhibit 2. The 2Q26 Beat Survives a Full Medical Development Normalization

The full-removal case remains favorable to both Street and Graver Research expectations; UnitedHealthcare and Optum Health account for most of the operating-earnings variance

Medicare improved enough to offset a worse commercial trend

UnitedHealthcare was the largest source of upside, with $3.94 billion of operating earnings versus $3.12 billion expected. The full-year floor increased to $12.0 billion from $10.8 billion. Medicare cost trend is now expected below the initial approximately 10% plan, retention was better than anticipated, and management expects Medicare Advantage enrollment to decline by roughly 1.1 million while margins finish above 3%. Benefit design, care management and network actions drove much of the improvement, although respiratory season, weather and favorable development also helped. Medical trend remains well above historical levels.

Commercial moved in the opposite direction. Cost trend is now modestly above 11%, with the No Surprises Act dispute-resolution process contributing roughly 50 basis points of incremental 2026 trend and at least 100 basis points in total. Higher coding intensity, cost per encounter and specialty-drug pressure are additional drivers. Management now expects full commercial margin recovery after 2027. Medicaid performance was broadly in line, with the 2026 margin outlook unchanged at negative 1.0% to negative 1.7%. The UnitedHealthcare guide raise is therefore Medicare-led; commercial remains the largest insurance-side uncertainty.

Optum Health was the second real positive; Insight included timing

Optum Health generated $1.174 billion of adjusted operating earnings versus $538 million of Street consensus and the $509 million Graver Research estimate. Its adjusted full-year floor increased to $2.215 billion from $1.577 billion. Clinical and operating improvements appear tangible—management cited an approximately 10% reduction in inpatient admissions from one scaled care-management initiative—but the quarter should not be annualized. Nearly all Optum Health earnings are expected in the first half, with a modest third-quarter profit offset by a modest fourth-quarter loss.

Optum Insight also beat, with $1.373 billion of adjusted operating earnings versus $1.160 billion expected, but some client transaction volume moved from the second half into the first. Its $4.75 billion adjusted full-year floor is unchanged. Optum Rx produced $1.490 billion versus $1.390 billion expected and retained its $6.25 billion guide. Both businesses remain approximately 55% second-half weighted. The formal 2026 reset is therefore concentrated where the operating evidence was strongest: UnitedHealthcare and Optum Health.

Exhibit 3. The 2026 Guidance Reset Is Concentrated in UHC and Optum Health

The adjusted segment operating-earnings floor increased by approximately $1.84 billion, entirely from UnitedHealthcare and Optum Health. First-half adjusted EPS of $13.61 implies a second-half midpoint of only $6.14.

A higher base, not a higher second-half run rate

Updated adjusted EPS guidance of $19.50 to $20.00 is well above the prior floor of $18.25, but the cadence remains back-end light. First-half adjusted EPS of $13.61 leaves $5.89 to $6.39 for the second half, or $6.14 at the midpoint. Management expects slightly more earnings in the third quarter than the fourth; UnitedHealthcare remains roughly 75% first-half weighted and Optum Health nearly entirely first-half weighted, while Insight and Rx provide the second-half offset.

The refreshed Bloomberg cadence confirms that the Street has not extrapolated the 2Q beat into a higher second-half run rate. Third-quarter EPS consensus increased to $4.02 from $3.70, while fourth quarter declined to $2.23 from $2.61; aggregate second-half EPS is essentially unchanged at $6.25 versus $6.31 pre-print. FY26 and FY27 consensus increased 6.5% and 6.1%, respectively. The FY27 segment revision is concentrated in UnitedHealthcare and Optum Health, which increased by approximately $1.00 billion and $485 million; Insight rose only $41 million and Rx declined $61 million.

Management described the $19.50 to $20.00 range as a durable stepping-off point for its 13% to 16% long-term growth algorithm, while acknowledging that the range includes favorable medical development. Current FY27 consensus of $22.32 represents 13.0% growth from the 2026 midpoint—effectively the low end of that framework. The estimate reset is credible, but delivery still depends primarily on insurance execution and Optum Health rather than a near-term acceleration in Insight or Rx.

Exhibit 4. Consensus Carries the Reset into 2027, Not into 2H26

Post-print consensus shifts earnings from 4Q into 3Q but leaves aggregate second-half EPS essentially unchanged. The FY27 operating-earnings revision is concentrated in UnitedHealthcare and Optum Health.

The market raised the earnings base without expanding the multiple

UNH entered the print with a demanding setup: shares rose 21.0% from April 21 through the July 15 pre-print close, versus 7.2% for the S&P 500 and 8.5% for XLV. Through July 21, the stock gained 4.3% while FY27 EPS consensus increased 6.1%, reducing the implied FY27 P/E from 19.9x to 19.5x. The earnings reset outpaced the stock; commercial trend and reserve quality prevented multiple expansion.

Reserve quality is supportive, but the 10-Q still matters

Release-level balance-sheet indicators lean supportive: medical costs payable increased 1.3% year over year while premium revenue declined 1.1%, and days claims payable of 47.0 was 2.5 days above 2Q25. DCP declined sequentially, which management attributed to normal seasonality. Without the incurred-period roll-forward, the reserve cushion cannot be fully reassessed until the 10-Q is filed.

Investment conclusion. The 2Q print confirms that the rebuild can produce cleaner earnings and a higher baseline, supported by real improvement in Medicare and Optum Health. It does not establish a broad medical-cost inflection. Further re-rating likely requires commercial pricing to catch up to trend, Medicare margins to survive the 2027 bid cycle, Optum Health to hold through the weaker second half, and the 10-Q reserve roll-forward to support the release-level indicators.

The problem was less the quarter than the path forward. July Medicaid rate updates were better than expected, membership and acuity were broadly in line, and management described the cost pressures as elevated but understood. Yet the full-year Medicaid operating margin outlook remained approximately negative 1.75%, management is not assuming material medical-cost trend improvement in the second half, and ELV expects additional market exits. The market wanted proof that better rates and operating actions were translating into margin recovery; 2Q26 offered a better setup, but not that proof.

Exhibit 1. 2Q26 at a glance

Subscribe now

The beat was real — just not fully recurring

The cleanest way to read the quarter is in three layers. First, reported adjusted EPS was $7.45. Second, removing the approximately $0.80 net below-the-line benefit produces roughly $6.65, still 7.1% above consensus. Third, management said operating outperformance was approximately $0.50, split about evenly between Medicare Advantage and Individual ACA. That makes the result meaningfully better than a one-time-assisted headline beat.

The tension is that strong benefit expense performance did not translate into year-over-year earnings growth. The 89.7% benefit expense ratio was 30 basis points better than StreetAccount consensus, but adjusted operating gain still declined 26.9% to $1.82 billion and adjusted operating margin fell 140 basis points to 3.6%. Health Benefits operating margin declined 170 basis points to 2.1%. In other words, the quarter beat a low bar while the underlying earnings base remains well below last year.

The guide rose to $27, but the recurring baseline is $26

ELV raised 2026 adjusted EPS guidance by $0.25 to at least $27.00, versus the $26.87 pre-print consensus. The full bridge is more informative than the headline. Management’s recurring earnings baseline increased from at least $25.75 to at least $26.00; approximately $0.25 of 2Q seasonality is expected to reverse in the second half, while $0.25 of operating strength is retained. The approximately $0.80 second-quarter below-the-line benefit is being redeployed into accelerated one-time investments and therefore contributes nothing net to the full-year guide.

The remaining $1.00 gap between the $26.00 recurring baseline and the $27.00 reported guide reflects the non-recurring investment-income benefit recognized in the first quarter. The raise is therefore recurring, but the reported guide is not the correct jumping-off point for 2027.

Exhibit 2. ELV’s $27 guide contains a $26 recurring earnings baseline

The bridge separates operating improvement from timing and non-recurring items. It also shows why the 2027 growth target begins at $26.00 rather than the reported $27.00 guide.

At least 12% growth from the $26.00 baseline implies a 2027 EPS floor of $29.12. That is only 7.9% above the reported 2026 guide. Current 2027 Bloomberg consensus is at $29.50, just $0.38 above management’s floor. The 2027 target is achievable on paper, but it leaves little room for slippage in the Medicaid recovery, Carelon growth, operating efficiency, or capital deployment assumed to support it.

Medicaid was not worse — but it was not better enough

The negative 1.75% Medicaid margin outlook is not new. ELV established it with fourth-quarter results in January, maintained it after the strong first-quarter print, and maintained it again in 2Q26. That continuity matters: the second quarter did not reveal a new acuity shock or a new step-up in cost trend. Management said membership and acuity remained broadly aligned with expectations, while the principal cost drivers — behavioral health, including ABA therapy; emergency department utilization; outpatient surgery; and specialty pharmacy — were familiar and actionable.

The disappointment is that the better rate picture did not change the full-year margin. July 1 rate updates moved toward the upper end of a mid-single-digit range, versus the lower end assumed at the start of the year. ELV expects the second-half margin to improve from 2Q26 as those rates and cost actions take hold, but it is not assuming material improvement in medical-cost trend. The company also confirmed its D.C. exit and expects to leave additional Medicaid markets over the next 12 to 18 months where it does not see a path to sustainable returns.

Our interpretation is that management is preserving room for volatility rather than signaling a hidden step-down in the business. Even so, unchanged guidance after better rates creates a burden of proof: either the rate upside is being absorbed by continued utilization pressure, or the company is holding conservatism that needs to convert into later upside.

Exhibit 2. Every 50 bps of Medicaid margin recovery is worth about $1.00 of EPS

At ELV’s current Medicaid revenue base, even partial margin recovery is material to the 2027 earnings algorithm. The sensitivity below illustrates why investors are focused so heavily on this one segment.

H1 Medicaid operating revenue was $28.72 billion, or a $57.45 billion annualized run rate. On that base, 50 basis points of margin recovery equates to approximately $287 million of operating income and $0.99 of after-tax EPS. A 100-basis-point recovery would contribute roughly $1.99 of EPS, or 64% of the $3.12 increase needed to reach the $29.12 floor. Full recovery from negative 1.75% to breakeven would be worth approximately $3.48 of EPS before considering revenue changes, market exits, or reinvestment. That is not our forecast, but it shows the scale of the embedded earnings drag — and the potential leverage if the turn materializes.

MA and ACA improved; Carelon was steady

Medicare Advantage. The deliberate 2026 portfolio reset is working. Favorable membership mix, better claims experience, and a greater concentration in D-SNP and HMO products generated roughly half of the quarter’s $0.50 operating outperformance. ELV remains on track for at least a 2% MA operating margin in 2026.

Individual ACA. The other half of the operating upside came from Individual ACA. A heavier mix of bronze plans produced more favorable early-year seasonality, and final 2025 CMS risk-adjustment results were better than estimated. ELV re-established the vast majority of that prior-year favorability in its 2026 accrual rather than extrapolating it, which explains why the quarter’s face-value upside did not flow through fully to guidance.

Carelon. Revenue increased 6.3% to $19.2 billion and operating gain increased 1.3% to $0.9 billion, while margin declined 30 basis points to 4.9%. CarelonRx benefited from specialty-pharmacy profitability, while Carelon Services continued to absorb investment as newer risk-based programs scale. The segment remains an important 2027 lever, but 2Q26 was steady rather than thesis-changing.

The stock reaction was a multiple reset, not an estimate reset

ELV entered the print with a demanding setup. Shares were up 30.1% from the April 21 close through July 14, versus 6.8% for the S&P 500 and 8.5% for XLV. The stock then fell 8.5% on July 15 and another 4.5% on July 16 before finishing essentially flat on July 17—a cumulative decline of 12.6% from the pre-print close.

Estimate revisions, however, were modest and positive—broadly consistent with the $0.25 guidance increase. Bloomberg consensus for 2026 EPS has risen $0.19 to $27.09, while 2027 consensus has increased $0.23 to $29.50. That disconnect indicates that the selloff was a multiple reset driven by execution risk and reduced earnings visibility, not a material reduction in expected earnings. That is the most important market message from the event.

Our take

We view 2Q26 as a fundamentally better quarter than the stock reaction implies, but not as proof that the Medicaid turn has arrived. The normalized EPS beat, MA progress, ACA execution, stronger Medicaid rates, and higher cash-flow guide are all constructive. Against that, the unchanged negative 1.75% Medicaid margin, the absence of assumed second-half cost-trend improvement, and the planned market exits keep the central earnings-quality debate unresolved.

The selloff reset the burden of proof. If second-half Medicaid margins improve as rates flow through, the $26 recurring baseline should support the $29.12 2027 floor and the current valuation could prove too punitive. If rate gains continue to be absorbed without visible margin progress, the market will question not only Medicaid’s recovery, but also how much of the 2027 algorithm must be supplied by Carelon, expense efficiency, and capital deployment.

What we are watching. The key evidence points are the 3Q26 Medicaid margin, the exit rate entering 2027, the scope of planned market exits, the durability of MA’s at least 2% margin, and measurable benefits from the one-time investments.

Preliminary revenue of $20.23 billion increased 8.7% year over year and was 3.9% above FactSet consensus. Adjusted EBITDA of $4.03 billion increased 4.6% and was 1.9% above consensus. Nevertheless, adjusted EBITDA margin declined roughly 80 basis points to 19.9%. HCA also reduced the midpoint of its 2026 adjusted EBITDA guidance by $250 million, or 1.6%, to $15.75 billion from $16.0 billion. All figures remain preliminary ahead of the July 24 earnings report.

Subscribe now

The headline beat was not a clean measure of operating momentum

Two roughly $400 million items shaped the quarter.

First, HCA estimated that the shift from health insurance exchange (HIX) coverage to uninsured status reduced second-quarter pretax income by approximately $400 million. That amount included a $75 million increase to the company’s prior estimate of the first-quarter impact.

Second, HCA recognized approximately $400 million of incremental Medicaid supplemental payment benefit, primarily related to Florida. The benefit covered October 1, 2024, through June 30, 2026, following approval of the state’s directed payment program.

The two items were similar in size but very different in character. The Florida benefit spans multiple reporting periods and therefore includes a substantial timing or catch-up component. The exchange headwind reflects the current economics of HCA’s payer mix and is embedded in the revised full-year outlook.

To frame the sensitivity, deducting the entire $400 million incremental Medicaid benefit from preliminary adjusted EBITDA yields approximately $3.63 billion, 8.2% below the preannouncement Street estimate and 5.8% below 2Q25. We would not treat $3.63 billion as normalized because some portion of the Florida benefit may recur. The exercise nevertheless shows why the preliminary $4.03 billion should not be treated as a clean quarterly run rate.

Patient traffic recovered, but surgical activity moved in the opposite direction

Exhibit 1. Broad patient traffic reaccelerated in 2Q26

Exhibit 2. Surgical volumes weakened despite higher admissions

Exhibits 1 and 2 highlight the key distinction. Broad patient traffic improved materially from 1Q26: admissions accelerated from 0.9% to 2.5%, equivalent admissions from 1.3% to 2.7%, and ER visits from 0.3% to 3.6%. The data therefore do not point to a system-wide demand contraction.

Surgical activity tells a different story. Inpatient surgery growth deteriorated to negative 2.3% in 2Q26 from negative 0.3% in 1Q26, while outpatient surgery growth weakened to negative 3.4% from negative 1.7%. Both were the weakest readings in the ten-quarter series.

The 4.8-percentage-point gap between admissions growth and inpatient surgery growth was also the widest in the period shown. The divergence is consistent with HCA’s description of a service-mix shift: hospitals saw more patients, but fewer encounters translated into surgical cases. That effect compounds the payer issue because elective and commercially insured surgical activity generally carries more favorable economics than uninsured or lower-acuity traffic.

The guidance bridge suggests a broader reset

The midpoint of revenue guidance remains unchanged at $78.25 billion, while the adjusted EBITDA midpoint declined by $250 million. On midpoint math, that implies roughly 30 basis points of lower EBITDA margin and reinforces that the reset is about conversion and mix rather than aggregate revenue.

Exhibit 3. Disclosed policy changes do not explain the full EBITDA guide cut

The two disclosed assumption changes produce a net $200 million benefit, yet the adjusted EBITDA midpoint fell by $250 million. The difference is an implied $450 million residual.

This is our calculation, not a company-provided bridge, and we would not label the entire residual “core” before the earnings call. It could reflect service mix, other operating assumptions, rounding, and any unquantified change in the expected contribution from HCA’s resiliency initiatives. Still, it is the most important unanswered question in the update, particularly because HCA also cited improved expense trends.

Using the revised midpoint, HCA’s preliminary first-half results imply approximately $7.92 billion of adjusted EBITDA in 2H26, roughly 0.8% below the $7.98 billion generated in 2H25. Put differently, the midpoint no longer assumes year-over-year adjusted EBITDA growth in the second half.

The stock is discounting more than a $250 million guide cut

HCA fell 6.9% on July 14, recovered 4.2% and 1.8% over the next two sessions, and then declined 3.7% on July 17. The shares ended the four-session period down approximately 5.0% from the July 13 close, despite the intervening recovery.

At $371.18, HCA is down 20.5% year to date, 14.2% since the April 24 first-quarter report, and 31.9% from its March 9 closing high of $545.13. The latest Street snapshot shows FY26 adjusted EBITDA of approximately $15.86 billion and FY27 adjusted EBITDA of $16.54 billion. Estimates have therefore moved far less than the share price.

That disconnect suggests the market is applying a larger discount for earnings quality and visibility, rather than simply processing the mechanical $250 million guidance reduction. Investors appear less willing to capitalize Medicaid payment timing and are demanding more evidence that the deterioration in uninsured and surgical mix is stabilizing.

What matters on the July 24 earnings call

The call needs to clarify five issues:

• How much of the $400 million Florida benefit was retroactive, and what portion is representative of the ongoing run rate?

• What was the 2Q26 HIX headwind excluding the $75 million first-quarter true-up, and is that run rate stabilizing?

• Was the surgical weakness concentrated by payer, service line, geography, or facility type?

• What accounts for the approximately $450 million residual in our midpoint guidance bridge?

• Does management remain confident in the previously discussed $400 million resiliency contribution?

Our preliminary conclusion is that broad hospital demand remains intact, but HCA’s earnings quality and visibility have deteriorated. The July 24 call can narrow that uncertainty, but the post-announcement price action indicates that investors are not yet willing to treat the headline 2Q26 adjusted EBITDA result as durable.

UnitedHealth Group is the largest and broadest company in healthcare services. With $447.6 billion of 2025 revenue, it spans health benefits, Medicare Advantage, Medicaid, pharmacy services, care delivery, health payments and healthcare technology. That breadth makes UNH relevant to nearly every major sector debate, but the immediate investment question is narrower: has the company reset medical costs, pricing and reserves onto an earnings base investors can again underwrite?

Confidence broke quickly in 2025. UNH affirmed adjusted EPS guidance of $29.50-$30.00 in January, cut the outlook in April and suspended it in May as Medicare Advantage utilization, new-member acuity and broader cost pressure exceeded expectations. By July, guidance had been re-established at only $16.00+, alongside an 89.4% MCR and unfavorable reserve development. The damage was not limited to the earnings reduction; it challenged a long-standing perception that UNH had superior forward visibility and unusually reliable guidance.

Managed-care accounting amplified the reset. Premiums and benefits are established largely in advance, while the related medical costs develop over subsequent months as claims are submitted and processed. Q1 is therefore especially estimate-dependent. When utilization and claims patterns are stable, this lag is manageable; when trend changes, a relatively small forecasting error can have a disproportionate impact on a low-margin insurer. The same annual repricing cycle can also support a rapid recovery if management correctly identifies the new cost base, although Medicaid rate adjustments typically lag.

Q1 2026 was encouraging but not conclusive. Adjusted EPS reached $7.23, the MCR improved to 83.9% and full-year guidance was raised, but the result benefited from favorable reserve development while underlying utilization remained elevated. By the second-quarter report, most Q1 claims will be substantially more developed and management will have an initial read on Q2 utilization. The print is therefore the first meaningful test of whether Q1 completed cleanly, reserves remain prudent and 2026 repricing is translating into durable margin recovery.

Exhibit 1 places that test in context, tracing the break in the prior earnings framework and the early stages of the 2026 recovery.

Exhibit 1. UNH Share Price: From the 2025 Reset to the 2Q26 Test

2Q26 Setup: Validation, Not Yet an Inflection

I expect 2Q26 to validate the Q1 setup rather than mark a new inflection. My estimate is $5.00 of adjusted EPS, 3% above Bloomberg consensus, on revenue of $111.6 billion. The upside is primarily MCR-driven, with UHC and Optum Health above consensus partly offset by modestly lower Optum Insight and Optum Rx estimates.

Exhibit 2. UNH 2Q26 Earnings Setup

My 88.3% MCR estimate is 15 basis points favorable to consensus and assumes modest favorable prior-period development as Q1 claims complete. It does not assume a material reduction in current medical cost trend. The expected read-through is that Q1 reserves were established prudently and that elevated utilization remains within the assumptions embedded in 2026 pricing.

At the segment level, I estimate $3.28 billion of UHC operating earnings at a 3.8% margin and $509 million of adjusted Optum Health operating earnings. My Insight and Rx estimates are slightly below consensus, reflecting their heavier second-half earnings cadence and continued investment and implementation costs.

At $5.00, first-half adjusted EPS would total $12.23, or 67% of the current $18.25 guidance floor - consistent with management’s expectation that roughly two-thirds of annual earnings will be generated in the first half. The setup is fundamentally constructive, but the stock has rerated materially since Q1. A clean validation print may support the recovery thesis without producing another outsized positive reaction; the hurdle for incremental upside is now better current-period trend, preserved reserve conservatism or a more substantive guidance raise.

Claims Completion and Reserve Quality: The Core 2Q Test

The reported MCR will matter less than the evidence beneath it: how Q1 claims completed, whether any favorability reflects reserve development or current-period trend, and what reserve position UNH carries into the second half.

Medical costs payable includes claims incurred but not yet received or processed. For recent service periods, UNH estimates the ultimate obligation using trend assumptions and completion factors - the percentage of claims expected to be visible at a given point. The company notes that billing lags can extend to 90 days and that approximately 90% of claims are known and settled within that period. A March 31 balance therefore still includes substantial estimation around February and March care activity; April and May provide a much more complete view.

That lag is benign when utilization, unit costs and submission patterns are stable, but it can create substantial earnings volatility when those relationships change. UNH’s 2025 experience is the relevant precedent: higher MA activity became visible late in Q1, then broadened as claims developed. By 2Q25, the company reported an 89.4% MCR and $70 million of unfavorable reserve development, nearly all tied to 2025 service dates.

The reserve position entering 2Q26 looks materially more conservative than a year ago.

Exhibit 3. UNH Enters 2Q26 With a More Conservative-Looking Reserve Position

Panel A. Medical Costs Payable Growth Outpaced Premium Growth by 561 bps in 1Q26

Panel B. Selected Reserve Indicators Entering 2Q26

UNH ended Q1 with $39.7 billion of medical costs payable, up 6.8% year over year, versus premium growth of only 1.2%. The resulting +561-basis-point reserve-growth spread compares with an ex-COVID historical average of +6 basis points; it is the strongest Q1 reading in my series back to 1Q19 and the second-highest non-COVID quarterly observation. DCP rose 3.1 days year over year to 48.6, while the roll-forward showed $1.05 billion of gross favorable prior-year development versus $320 million in 1Q25. Management characterized the net enterprise benefit as slightly above $500 million and said it had re-established a similarly prudent reserve position at March 31.

These metrics are supportive, not dispositive. Faster reserve growth may reflect added conservatism, but it can also reflect a larger underlying claims liability; DCP is also affected by mix, payment timing and Part D mechanics. The 2Q report therefore needs to establish three points: Q1 claims complete without adverse current-year development; current utilization remains within pricing assumptions; and the June reserve position stays prudent after any favorable development is recognized.

My 88.3% MCR estimate assumes modest favorable development and no material improvement in underlying trend. The highest-quality outcome is not simply a lower MCR, but a return to the operating pattern that historically supported UNH’s earnings consistency: cautious initial estimates, favorable claims development and sufficient reserve cushion for the seasonally more difficult second half.

UHC: Testing the Pricing Reset

UnitedHealthcare (UHC) is the clearest path to 2026 earnings recovery. At the July 2025 reset, management estimated medical costs were $6.5 billion above the original plan - $3.6 billion in Medicare, $2.3 billion across commercial and exchange products and the balance in Medicaid. The 2026 response is straightforward: price and design products around the higher cost base, accept membership contraction where returns are inadequate and restore margins before pursuing growth.

The recovery does not require medical trend to normalize; it requires pricing to remain ahead of an elevated trend environment. In MA, UNH entered 2025 with pricing based on just over 5% trend, versus an eventual 7.5% outcome. The 2026 bids assume trend approaching 10%. That is not a simple 250-basis-point cushion: roughly two-thirds of the increase reflects known provider-rate and fee-schedule changes, while the remainder accommodates less predictable risks. Residual utilization is assumed to remain high but stable.

The early evidence is favorable. Management described Q1 MA trend in the 7%-8% range against the approximately 10% pricing assumption, with modest favorability across government programs continuing through April. UHC’s Q1 operating margin increased 40 basis points year over year to 6.6%, despite MA and commercial risk membership contraction. My 2Q estimate of $3.28 billion of operating earnings and a 3.8% margin assumes that pricing alignment continues without a further trend inflection.

For Medicare, a clean quarter should preserve the expected roughly 50-basis-point margin recovery while MA membership contraction remains near 1.3 million lives. The volume loss largely reflects deliberate plan exits, benefit changes and a shift away from less manageable products. The appropriate trade-off is lower membership with adequate pricing rather than another year of volume retention at subeconomic margins. The warning sign would be attrition moving materially beyond plan without the expected margin benefit.

Commercial follows the same framework. Group trend remains near 11%, and the risk book has been repriced accordingly. At March 31, commercial risk membership was down 685,000 year over year while fee-based membership increased 750,000, reflecting both pricing discipline and migration toward self-funded products. More than 500,000 of the risk decline relates to the exchange business, which is small in the context of UNH earnings. The more important test is whether group renewals continue to close the margin gap without materially worse retention.

Medicaid remains the exception. State rate updates lag acuity and trend, limiting UHC’s ability to reprice on its own timetable. Management entered 2026 assuming 6%-7% aggregate rate increases but still expects rates to remain below trend, leaving the business in a loss position this year. April 1 and July 1 rate actions will be important, but Medicaid is unlikely to contribute meaningful upside.

The current evidence supports pricing ahead of trend in Medicare and commercial, but not Medicaid. Q2 needs to confirm that elevated utilization remains within the new assumptions, margin recovery is arriving alongside the planned membership contraction and the pricing cushion has not begun to erode.

Optum: Segment Cadence Matters

Optum is unlikely to determine whether the consolidated print is fundamentally clean; medical costs and reserves remain the primary drivers. It can, however, materially affect earnings quality. Optum Health, Insight and Rx have different seasonal profiles, so sequential growth is a poor common benchmark.

Optum Health reported $1.31 billion of adjusted operating earnings at a 5.4% margin in Q1 - more than 80% of the initial full-year adjusted floor of $1.58 billion. That is not a sustainable quarterly run rate. Following the transfer of Optum Financial to Insight, Optum Health more closely resembles a risk-bearing care-delivery business and is heavily first-half weighted. My $509 million estimate at a 2.2% margin therefore assumes a deliberate sequential decline, not renewed deterioration.

The quarter should be assessed on a clean adjusted basis. Reported 2026 guidance includes $623 million of earnings from amortizing the loss-contract reserve established in 4Q25, while adjusted guidance excludes that benefit. The accounting amortization does not represent current-year operating improvement. The key tests are no further contract or portfolio charges, no increase in the reserve and continued progress toward repricing or exiting the affected third-party contracts for 2027.

Insight and Rx are more back-half weighted, with management expecting each to generate approximately 60% of annual earnings in 2H26. At Insight, older products are being decommissioned while AI-enabled offerings are developed and commercialized. My $1.06 billion earnings estimate at a 20.1% margin is modestly below consensus; a small shortfall would be acceptable if the back-half cadence and new-product sales remain intact.

Optum Rx is absorbing implementation costs for nearly 800 new clients while UHC membership contraction reduces internal volume. My $1.56 billion estimate at a 4.1% margin is also modestly below consensus and the approximately 4.2% full-year target. The relevant read-through is whether onboarding remains on schedule and external wins, productivity and second-half volume can offset the internal membership headwind.

A clean Optum quarter may therefore appear mixed on a sequential basis: a sharp step-down at Health and only partial progress at Insight and Rx. The appropriate test is cadence. Health must deliver a clean step-down without another reset; Insight and Rx must preserve a credible second-half ramp.

Guidance and Capital Deployment

The headline question is whether UNH raises the adjusted EPS floor above $18.25. At my $5.00 2Q estimate, first-half EPS would reach $12.23, or 67% of the current floor, broadly consistent with management’s expectation that slightly under two-thirds of annual earnings will be generated in 1H26. That supports a higher floor if the operating assumptions remain intact.

The source matters more than the size. A raise supported by stable current-period trend, UHC margin recovery and clean Optum execution would de-risk the earnings base. The same increase driven mainly by reserve development, taxes or share-count accretion would be less informative. A modest raise - or even a maintained floor - could still be high quality if management preserves reserve cushion and reinvests some upside.

Capital deployment is a secondary confidence signal. Initial guidance contemplated more than $18 billion of operating cash flow, approximately $2.5 billion of repurchases and a return toward 40% debt-to-capital. Q1 delivered $8.9 billion of operating cash flow, reduced leverage to 42.9% and accelerated at least $2 billion of buybacks into the first half. Because that amount was pulled forward rather than added to the annual plan, completion is expected. The incremental signal is whether UNH raises the full-year repurchase outlook while continuing to delever.

The strongest update would show that both a higher EPS floor and additional capital return are funded by a stronger operating and cash-flow base.

2Q Outcome Framework

Headline EPS alone will not determine the quality of the print. The key variables are Q1 claims completion, current medical cost trend, the June reserve position and the credibility of the second-half segment and guidance cadence.

Exhibit 4. UNH 2Q26 Outcome Framework

My modeled outcome is a clean print: Q1 claims complete favorably, producing an MCR approximately 15 basis points better than consensus; underlying utilization remains elevated but within 2026 pricing; UHC margin recovery stays on track; Optum Health is clean despite the expected sequential decline; and guidance is raised or meaningfully de-risked. Favorable prior-period development is part of the positive read-through, provided UNH also preserves a prudent June reserve position.

A mixed print would deliver an acceptable headline MCR but leave current-period trend, ending reserve quality or the second-half Optum cadence less clear. The recovery would remain intact, but the quarter would do little to advance the trust rebuild.

A weak print would show adverse current-year development, renewed utilization acceleration or a narrowing UHC pricing cushion. Any need to defend guidance through reserve releases or unrelated offsets would reopen the 2025 credibility concerns.

A clean print is my fundamental base case. It is not necessarily a call for an outsized positive share-price reaction: after the rerating since Q1, validation is increasingly reflected in the stock and the hurdle for incremental upside is materially higher.

Conclusion: The First Real Test

Q1 established that the recovery could be real; Q2 must show that it is durable. My base case is a clean print: favorable Q1 claims completion, elevated but controlled current trend, continued UHC margin repair, Optum performance consistent with the planned cadence and a higher or meaningfully de-risked full-year outlook.

The standard is higher than a consensus beat. Reserve development is valuable only if underlying trend and the June reserve position remain sound, while a guidance raise matters most when supported by operating performance rather than taxes, reserve releases or buybacks. Given the stock’s rerating, a clean result may validate the recovery without driving another outsized reaction, but it would materially strengthen the 2026 earnings base ahead of a fuller company view after the quarter.

Graver Research exists to bring the discipline of professional equity research to a broader and more accessible format.

The goal is to apply the same core habits that make institutional research valuable — clear coverage universes, explicit debates, evidence-based company analysis, industry context, earnings and policy read-throughs, and a disciplined focus on what can change the narrative — while publishing in a format that is useful to both investors and healthcare services professionals.

Traditional equity research is often written for institutional clients and distributed through enterprise relationships, banking platforms, and sales channels that most serious readers cannot access regardless of interest or willingness to pay. Graver Research is built around a different model: independent, sector-focused research that is more accessible, more flexible in format, and designed for readers who want to understand how healthcare services companies, policy, reimbursement, utilization, and market expectations fit together.

Some of the topics, terms, and business models in healthcare services are complex and highly specific. The core product is written for industry and healthcare investment professionals, but Graver Research will also publish primers and explainers for readers who are newer to the space or want a clearer foundation.

Subscribe now

Why this map exists

This “Healthcare Services Coverage Map” note is intended to be both the initial launching point for Graver Research and serve as a key regularly updated reference piece for subscribers. The map defines the Graver Research coverage universe and what subscribers should expect to receive on an ongoing basis. It also outlines the key company and subsector debates, and creates a baseline for future updates as earnings, policy developments, industry data, and market narratives change.

This piece does not serve as a full initiation or valuation framework for the coverage universe. Going forward, Graver Research will publish a mix of company notes, sector signals, policy and regulatory read-throughs, data snapshots, earnings/event notes, and recurring coverage maps. The common thread will be the same: identify the debates that matter, connect company fundamentals to industry and policy context, and update the view as the facts change.

What “healthcare services” means

Healthcare services is often used as a catch-all label for the parts of the healthcare industry that are not biopharma, medical technology, or life sciences tools. Those categories are often centered on products: drugs, devices, diagnostics, equipment, or research inputs. Healthcare services is different. It is more about systems, infrastructure, payment flows, care delivery, distribution, administration, outsourcing, and execution.

That makes the category broad and sometimes imprecise. A managed care company, a hospital operator, a drug distributor, and a clinical research organization all sit in different parts of the healthcare value chain. They have different customers, margin structures, regulatory exposures, capital intensity, and earnings drivers. But they share a common feature: each helps determine how healthcare is financed, accessed, delivered, administered, or supported.

In that sense, healthcare services is the operating layer of the healthcare system. It includes the companies that insure members, manage medical cost risk, contract with providers, deliver care, distribute drugs, process claims, run networks, support clinical development, manage data, and help large healthcare organizations function. The sector is where policy, reimbursement, utilization, labor, contracting, local market structure, and corporate execution show up most directly in public company fundamentals.

That is also what makes the sector difficult to analyze as one simple group. The key variables for a Medicare Advantage payer are not the same as the key variables for a hospital operator or pharmaceutical distributor. A utilization trend that pressures one subsector may benefit another. A reimbursement change may matter differently depending on payer mix, geography, customer concentration, or the ability to reprice risk. The same healthcare headline can therefore produce very different business implications across the group.

The initial coverage universe

Graver Research will begin with an initial coverage universe of 10 public companies that are among the most important for tracking the broader narratives, earnings debates, and policy implications across healthcare services.

This list is not meant to be exhaustive. The broader public healthcare services universe includes more than 100 companies across managed care, providers, distribution, services, technology, outsourcing, diagnostics, post-acute care, physician enablement, and adjacent areas. Graver Research will follow that broader universe where relevant, but the goal of the initial coverage list is to create a focused anchor group that can be covered consistently and thoughtfully.

The starting universe spans four major subsectors: managed care, hospitals, healthcare distribution, and CRO / outsourcing. These groups represent a large share of public healthcare services market capitalization and sit at the center of many of the sector’s most important current debates: medical cost trend, Medicare Advantage economics, Medicaid and ACA normalization, hospital volume and labor dynamics, specialty distribution growth, capital allocation, biopharma outsourcing demand, and the relationship between policy change and company-level earnings power.

Over time, this universe will likely broaden and evolve. Companies may be added as new debates become more important, or as adjacent subsectors deserve more dedicated coverage. For now, these 10 companies provide a practical starting point: large, liquid, strategically relevant businesses that together offer a useful lens into the state of healthcare services.

Exhibit 1 below provides a simple starting snapshot of the initial coverage universe: Market Capitalization, forward revenue, primary valuation, and recent total return performance.

Exhibit 1: Coverage Universe Snapshot

How the subsectors have traded

Healthcare services does not trade as one unified group. The divergence is clear in Exhibit 2 below, and it reflects a broader point about the sector: different subsectors can be exposed to the same underlying healthcare driver in very different ways.

Utilization is a simple example. Rising healthcare utilization can be positive for hospitals if it supports volumes, acuity, and operating leverage. It can be positive for distributors if it flows through prescription or specialty drug volumes. It can be negative for managed care companies if medical cost trend is underpriced or emerges faster than rates and benefit design can adjust. For CROs and outsourced services companies, near-term stock performance may have less to do with medical utilization and more to do with biopharma funding, backlog conversion, and customer spending cycles.

Even that framing is too static. These relationships can change over time depending on pricing, policy, contract structure, payer mix, market expectations, and the starting point for each stock. A driver that looks like a headwind in one period can become manageable if it is repriced. A favorable end-market trend can still disappoint if expectations were too high. As with any public company, the market reaction is rarely just about the direction of the driver; it is about the driver relative to expectations.

That is why healthcare services needs to be analyzed by subsector and company-specific debate, not as a single monolithic category. Performance can diverge sharply across managed care, hospitals, distribution, and CRO / outsourcing. It can also vary meaningfully within a subsector. In managed care, for example, exposure to commercial risk, Medicare Advantage, Medicaid, ACA marketplaces, PBMs, and care delivery assets can lead to very different earnings sensitivities and investor debates.

Exhibit 2 shows how the four initial subsectors covered by Graver Research have performed over the past three years. The baskets use a broader group of stocks than the initial 10-company coverage universe in order to better represent subsector-level performance. The constituents are listed in the caption below the chart.

Exhibit 2: 3-Year Indexed Total Return by Subsector

The key company debates

Each company in the initial coverage universe has a different setup. Some are working through utilization and reimbursement resets. Others are trying to prove the durability of specialty growth, PBM model changes, vertical integration, or biopharma demand recovery. Even within the same subsector, the stock debates can be very different.

Exhibit 3 below is meant to track the current narrative for each company. The goal is to identify the live debate, the evidence that could change investor perception, and the key variables that should matter most over the next several quarters.

Future company specific notes will go deeper on each of these debates, beginning with UNH.

Exhibit 3: Coverage Debate Tracker

The subsector setup

The initial coverage universe spans four broad subsectors: managed care, hospitals, distribution, and CRO / outsourcing. Each group sits in a different part of the healthcare services value chain, but each is exposed to the same broad question: how do changes in utilization, reimbursement, policy, market structure, and customer behavior flow through to company-level earnings power?

Managed Care

Managed Care is the largest and most complex debate. The group is working through overlapping resets in Medicare Advantage, Medicaid, ACA marketplaces, PBM transparency, commercial pricing, vertical integration, and public / regulatory scrutiny. The central question is whether 2025 and 2026 represent a painful but manageable reset, or whether normalized earnings power is structurally lower than investors previously assumed.

Medicare Advantage is the most visible pressure point. HUM is the purest test because its recovery depends heavily on Stars, benefit design, utilization, retention, and the ability to rebuild MA margins over the next several years. UNH and CVS also have meaningful MA exposure, but their debates extend into broader platforms and services. Medicaid and ACA add another layer. ELV and CNC are the clearest examples of companies trying to show that rate catch-up, cost management, repricing, and risk adjustment can restore margins after a period of elevated trend and morbidity pressure. CI provides the counterpoint: a more employer-focused and asset-light services driven model where the debate is less about government-program funding and more about PBM transition, commercial discipline, specialty pharmacy, and capital return.

Across the group, the most important question is whether managed care companies can still price, design benefits, manage cost, and adapt fast enough to protect long-term earnings power in a more difficult utilization and policy environment.

Hospitals

Hospitals have a different setup. Utilization is generally a positive driver when it supports admissions, acuity, operating leverage, and commercial revenue. HCA is the clearest hospital benchmark because it combines scale, strong local-market networks, disciplined capital allocation, outpatient expansion, and a long track record of cost control. The debate is not whether HCA is a high-quality operator. It is whether even a high-quality operator can fully absorb policy and payer-mix pressure.

ACA exchange attrition can reduce volumes, shift patients toward uninsured status, pressure collections, and change utilization patterns. Supplemental payments can offset some of that pressure, but they are variable and difficult to underwrite. Labor and hospital-based physician costs also remain important. The hospital setup is therefore a balance between attractive core demand and the reality that coverage, reimbursement, and payer mix can still materially influence reported earnings.

Distribution

Distribution is no longer just a low-margin drug logistics story. MCK and COR both show how scale distribution is becoming a foundation for specialty-enabled healthcare services. Specialty drug utilization, oncology innovation, GLP-1s, biosimilars, health-system services, provider relationships, biopharma services, workflow tools, and capital allocation are now central to the debate.

MCK represents the cleaner specialty-led compounder, with oncology, multispecialty, CoverMyMeds, biopharma access services, data, and portfolio simplification supporting the growth story. COR is making a more direct move into specialty physician infrastructure through OneOncology, Retina Consultants of America, and EyeSouth. The key question for both is whether specialty services can sustain premium earnings growth after a strong period of execution, or whether growth normalizes as GLP-1 revenue, biosimilars, customer shifts, list-price changes, and acquisition contribution mature.

CRO / Outsourcing

Contract Research Organizations and Outsourcing is centered on biopharma demand recovery and AI. IQV is the primary lens because it spans clinical development, commercial outsourcing, real-world data, analytics, and life-sciences technology. The first question is whether large pharma decision-making and biotech funding are improving enough to support sustained bookings, backlog conversion, and revenue growth. The second is whether AI is a threat or a moat.

IQV is arguing that useful AI in life sciences requires proprietary data, compliance, domain expertise, and embedded workflows. If that is right, AI can become a revenue and margin opportunity. If not, parts of CRO, analytics, and consulting work could face pricing or automation pressure. That makes IQVIA the cleanest test of whether CRO / outsourcing can reaccelerate after several years of uncertainty.

What Graver Research will track

The goal is to understand which developments actually matter for normalized earnings power, competitive position, and long-term business value.

That requires combining multiple inputs. Company filings, earnings calls, investor presentations, and quantitative company data are the starting point. Industry data helps supplement and test management commentary. Conversations with operators, investors, consultants, and others across the healthcare ecosystem can help assess whether the public narrative matches what is happening in the field. My decade of experience following healthcare services companies over multiple cycles provides the context for separating signal from noise.

The research framework will focus on the variables that most often drive healthcare services fundamentals.

Utilization is one of the most important. Changes in admissions, procedures, pharmacy volume, acuity, care intensity, and site of care can create very different implications across subsectors. Higher utilization may be positive for hospitals or distributors, negative for managed care if underpriced, and less directly relevant for CROs in the near term.

Reimbursement and rate cycles are equally important. Medicare Advantage rates, Medicaid rate updates, commercial pricing, supplemental payments, exchange pricing, and manufacturer / distributor economics often determine whether cost pressure can be absorbed or repriced. Policy and regulation matter because healthcare services business models are deeply connected to government programs, payment rules, risk adjustment, PBM scrutiny, prior authorization, transparency requirements, and coverage policy.

Membership and enrollment will also be central, especially in managed care. Growth is not automatically good if it comes with worse morbidity, weaker retention, underpriced risk, or unattractive lifetime value. Payer mix matters for providers because a volume trend can look very different depending on whether it is commercial, Medicare, Medicaid, exchange, or uninsured.

Labor and capacity remain critical for facility-based care and care delivery businesses. Wage inflation, contract labor, physician costs, throughput, staffing models, and capital investment can determine whether revenue growth converts into margin. Medical cost trend is the managed care equivalent: the key question is not just whether cost trend is high, but whether it is understood, priced, managed, and reflected in expectations.

Across all subsectors, Graver Research will track contracting power, capital allocation, earnings quality, and valuation.

The objective is to build a disciplined research process around the variables that matter. Not every headline changes the story. The work is to identify which facts actually change the debate.

How this map will evolve

This coverage map is meant to be a starting point, not a static document. Graver Research will update it periodically as company fundamentals, subsector narratives, policy developments, and market expectations change.

The likely cadence will be quarterly, but the map may be updated sooner if the facts change materially. In healthcare services, narratives can move quickly: a rate notice, reimbursement update, utilization inflection, policy proposal, acquisition, or management change can alter the debate before the next formal reporting cycle.

Future versions may add companies, refine the subsector groupings, change the key variables being tracked, or reframe the central debate for individual names.

The next piece will move from the map to company-level work, beginning with UNH. That note will go deeper on one of the most important current debates in healthcare services: whether UNH’s recent reset is the beginning of a recovery in normalized earnings power or evidence of a more durable impairment.